CLINICAL STUDY PROTOCOL
Study Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study 
to Evaluate the Efficacy and Safety of GS-5245 for the Treatment 
of COVID-19 in Nonhospi[INVESTIGATOR_419760]: Study of GS-5245 in Nonhospi[INVESTIGATOR_419761]-19 
Sponsor: [COMPANY_009] Sciences, Inc.
[ADDRESS_529378]
Foster City, CA [ZIP_CODE]
[LOCATION_003]
IND Number: [ADDRESS_529379] Number: 2023-503277-38
ClinicalTrials.gov 
Identifier:[STUDY_ID_REMOVED]
Indication: COVID-19 
Protocol ID: GS-US-611-[ADDRESS_529380] Information: The medical monitor name [CONTACT_3669] [CONTACT_54611].
Protocol 
Version/Date:Amendment 4: 12 December 2023 
Amendment History: Original: 14 September 2022
Amendment 1: 05 December 2022
Amendment 2: 20 January 2023
Amendment 3: 21 March 2023
High-level summaries of the histories of amendments are provided 
in Appendix 11.8.
Country-specific 
Requirements:Country-specific requirements, as applicable, are listed in 
Appendix 11.7.
GILEAU 
This study will be conducted in compliance with this protocol and in accordance with the ethical 
principles that have their origin in the Declaration of Helsinki, and that are consistent with 
International Council for Harmonisation (ICH) Good Clinical Practice (GCP) and applicable 
regulatory requirements.
CONFIDENTIALITY STATEMENT
The information contained in this document, particularly unpublished data, is the property or 
under control of [COMPANY_009] Sciences, Inc., and is provided to you in confidence as an investigator, 
potential investigator, or consultant, for review by [CONTACT_10825], your staff, and an applicable 
institutional review board or independent ethics committee. The information is only to be used 
by [CONTACT_54612]. You will not disclose any of the information to others without written 
authorization from [COMPANY_009] Sciences, Inc., except to the extent necessary to obtain informed 
consent from those persons to whom the drug may be administered.
GS-[ADDRESS_529381] OF ABBREVIATIONS AND DEFINITION OF TERMS ...................................................................................7
PROTOCOL SYNOPSIS..............................................................................................................................................10
STUDY SCHEMA........................................................................................................................................................15
STUDY PROCEDURES TABLE ................................................................................................................................16
1. INTRODUCTION................................................................................................................................................19
1.1. Background..............................................................................................................................................19
1.2. Background on Study Interventions ........................................................................................................20
1.2.1. GS-5245.................................................................................................................................20
1.3. Rationale for This Study..........................................................................................................................29
1.4. Rationale for Dose Selection of GS-5245 ...............................................................................................29
1.5. Risk/Benefit Assessment for the Study ...................................................................................................[ADDRESS_529382] to Follow-up ..................................................................................................................35
3.4. Definitions for Time of Primary Endpoint and End of Study .................................................................35
3.4.1. Primary Endpoint...................................................................................................................35
3.4.2. End of Study..........................................................................................................................36
3.5. Source Data .............................................................................................................................................36
4. PARTICIPANT POPULATION..........................................................................................................................37
4.1. Number of Participants and Participant Selection...................................................................................37
4.1.1. Participant Replacement........................................................................................................37
4.2. Inclusion Criteria.....................................................................................................................................37
4.3. Exclusion Criteria....................................................................................................................................38
5. STUDY INTERVENTIONS AND CONCOMITANT MEDICATIONS ...........................................................40
5.1. Randomization, Blinding, and Treatment Code Access..........................................................................40
5.1.1. Randomization.......................................................................................................................40
5.1.2. Blinding .................................................................................................................................40
5.1.3. Planned Interim Internal Unblinding.....................................................................................40
5.1.4. Procedures for Breaking the Blind on Treatment Codes.......................................................41
5.2. Description and Handling........................................................................................................................41
5.2.1. Formulation ...........................................................................................................................41
5.2.2. Packaging and Labeling ........................................................................................................41
5.2.3. Storage and Handling ............................................................................................................42
5.3. Dosage and Administration .....................................................................................................................42
5.4. Prior and Concomitant Medications........................................................................................................42
5.4.1. Prior and Concomitant Medications That Are Prohibited.....................................................42
GS-5245
Protocol GS-US-611-6549 Final
[COMPANY_009] Sciences, Inc. Amendment 4
CONFIDENTIAL Page 4 12 December [ZIP_CODE].5. Accountability for Study Drug(s)............................................................................................................43
5.5.1. Study Drug Return or Disposal .............................................................................................43
6. STUDY PROCEDURES......................................................................................................................................44
6.1. Informed Consent (and Assent as Applicable)........................................................................................[ADDRESS_529383]/Independent Ethics Committee Review and 
Approval................................................................................................................................72
9.1.4. Informed Consent ..................................................................................................................72
9.1.5. Confidentiality.......................................................................................................................73
9.1.6. Study Files and Retention of Records ...................................................................................73
9.1.7. Electronic Case Report Forms...............................................................................................75
9.1.8. Investigator Inspections.........................................................................................................75
9.1.9. Protocol Compliance .............................................................................................................75
9.2. Sponsor Responsibilities .........................................................................................................................75
9.2.1. Protocol Modifications ..........................................................................................................75
9.2.2. Study Reports and Publications.............................................................................................76
9.3. Joint Investigator/Sponsor Responsibilities ............................................................................................76
9.3.1. Payment Reporting ................................................................................................................76
9.3.2. Access to Information for Monitoring...................................................................................76
9.3.3. Access to Information for Auditing or Inspections ...............................................................76
9.3.4. Study Discontinuation ...........................................................................................................77
10. REFERENCES.....................................................................................................................................................78
11. APPENDICES......................................................................................................................................................80
11.1. Investigator Signature [CONTACT_3490].....................................................................................................................81
11.2. Authorization Status of Study Interventions ...........................................................................................82
11.3. Pandemic Risk Assessment and Mitigation Plan ....................................................................................83
11.4. Pregnancy Precautions, Definition of Childbearing Potential, and Contraceptive Requirements ..........86
11.5. Underlying Medical Conditions Associated With Higher Risk for Severe COVID-19..........................89
11.6. Patient Reported Outcomes .....................................................................................................................91
11.7. Country-Specific Requirements ..............................................................................................................92
11.8. Amendment History ................................................................................................................................93
11.8.1. Amendment 4 (12 December 2023) ......................................................................................93
11.8.2. Amendment 3 (21 March 2023) ............................................................................................93
11.8.3. Amendment 2 (20 January 2023) ..........................................................................................94
11.8.4. Amendment 1 (05 December 2022) ......................................................................................[ADDRESS_529384] OF IN-TEXT TABLES
Table 1. Study Procedures Table ...........................................................................................................16
Table 2. GS-US-611-6248: Plasma Pharmacokinetic Parameters of GS-441524 in Single 
Ascending Dose Cohorts 1 Through 4 ....................................................................................24
Table 3. GS-US-611-6248: Plasma Pharmacokinetic Parameters of GS-441524 in Multiple 
Ascending Dose Cohorts 5 and 6 ............................................................................................24
Table 4. GS-US-611-6248: PBMC Pharmacokinetic Parameters of GS-443902 in Multiple 
Ascending Dose Cohorts 5 and 6 ............................................................................................25
Table 5. GS-US-611-6409: Plasma Pharmacokinetic Parameters of Midazolam in Cohort 3..............27
Table 6. GS-US-611-6409: Plasma Pharmacokinetic Parameters of Pi[INVESTIGATOR_419762] 5..............27
Table 7. GS-US-611-6409: Plasma Pharmacokinetic Parameters of GS-441524 in Cohort 1..............28
Table 8. GS-US-611-6409: Plasma Pharmacokinetic Parameters of GS-[ADDRESS_529385] + (C last/λz)
AUC last area under the concentration versus time curve from time zero to the last 
quantifiable concentration
AUC tau area under the concentration versus time curve over the dosing interval
AUC x-xx partial area under the concentration versus time curve from time “x” to time “xx”
C24 concentration at [ADDRESS_529386]-dose
CFR Code of Federal Regulations
CI confidence interval
CL cr creatinine clearance
CL r renal clearance of unchanged drug in a specific interval (CL r (interval) ) or 
cumulatively over all collection intervals
Cmax maximum observed concentration of drug
COVID-[ADDRESS_529387] ratio
IB investigator’s brochure
IC50 half-maximal inhibitory concentration)
ICF informed consent form
ICH International Council for Harmonisation (of Technical Requirements for 
Pharmaceuticals for Human Use)
IEC independent ethics committee
IND investigational new drug
IRB institutional review board
IRT interactive response technology
IV intravenous
LLOQ lower limit of quantitation
LPLV last participant’s last visit
MAV medically attended visit
MDZ midazolam
MedDRA Medical Dictionary for Regulatory Activities
MET metformin
NOAEL no observed-adverse-effect level
NRU neutral red uptake
OATP organic anion transporting polypeptide
OCT organic cation transporter
PBMC peripheral blood mononuclear cell
PCR polymerase chain reaction
P-gp P-glycoprotein
PIT pi[INVESTIGATOR_419763](s)
PROMIS-29 Patient-Reported Outcomes Measurement Information System-29
PRO patient-reported outcome
RDV remdesivir 
RNA ribonucleic acid
RT-qPCR reverse transcriptase-quantitative polymerase chain reaction
RWD real-world data
SAE serious adverse event
SARS-CoV-2 severe acute respi[INVESTIGATOR_6507] 2
SSR special situation report
t1/2 elimination half-life
GS-5245
Protocol GS-US-611-6549 Final
[COMPANY_009] Sciences, Inc. Amendment 4
CONFIDENTIAL Page 9 12 December 2023TK toxicokinetic(s)
ULN upper limit of normal
US [LOCATION_002]
WPAI + CIQ: COVID19 Work Productivity and Activity Impairment + Classroom Impairment Questions: 
COVID-[ADDRESS_529388]
Foster City, CA [ZIP_CODE]
Study Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate 
the Efficacy and Safety of GS-5245 for the Treatment of COVID-19 in Nonhospi[INVESTIGATOR_419764]: Study of GS-5245 in Nonhospi[INVESTIGATOR_419761]-19
IND Number: [ADDRESS_529389] Number: 2023-503277-38
Study Registry ID: [REMOVED]
Study Centers Planned:  Approximately 300 centers globally
Objectives and Endpoints: 
Primary Objectives Primary Endpoints 
•To evaluate the efficacy of GS-5245 in reducing 
the duration of COVID-19 symptoms•Time to COVID-19 symptom alleviation by 
[CONTACT_2006] 29 
•To evaluate the safety and tolerability of 
GS-5245 administered in nonhospi[INVESTIGATOR_419765]-19•Incidence of treatment-emergent adverse events 
(AEs) and laboratory abnormalities
•Incidence of serious AEs (SAEs) and AEs 
leading to study drug discontinuation
Secondary Objectives Secondary Endpoints
•To assess the impact of GS-5245 on time to 
resolution of COVID-19 symptoms 
•To evaluate the impact of GS-5245 on moderate 
relapse of COVID-19 symptoms•Time to COVID-19 symptom resolution by 
[CONTACT_2006] 29 
•Proportion of participants with moderate relapse 
of COVID-19 symptoms by [CONTACT_2006] 29
•To evaluate the efficacy of GS-5245 in reducing 
COVID-19–related medically attended visits 
(MAVs) or all-cause death•Proportion of participants with COVID-19–
related MAVs or all-cause death by [CONTACT_2006] 29
•To evaluate the efficacy of GS-5245 in reducing 
COVID-19–related hospi[INVESTIGATOR_103151]-cause 
death•Proportion of participants with COVID-19–
related hospi[INVESTIGATOR_419766]-cause death by 
[CONTACT_2006] 29
•To evaluate the antiviral activity of GS-5245 on 
SARS-CoV-2 nasal swab viral load at Day 5•Change from baseline in SARS-CoV-2 nasal 
swab viral load at Day 5
•To evaluate the effect of GS-5245 on duration of 
viral shedding •Time to antigen negativity
GS-5245
Protocol GS-US-611-6549 Final
[COMPANY_009] Sciences, Inc. Amendment 4
CONFIDENTIAL Page 11 12 December 2023•To evaluate the effect of GS-5245 on viral 
rebound•Proportion of participants with viral antigen 
rebound
•To evaluate the plasma PK of GS-441524 
(metabolite of GS-5245) 
•To evaluate the impact of GS-5245 on relapse of 
COVID-19 symptoms•Plasma concentrations and PK parameters 
AUC tau, Ctau, and C max of GS-441524, as 
available
•Proportion of participants with relapse of 
COVID-19 symptoms by [CONTACT_2006] 29
Study Design: This Phase 3 study will be a global randomized, double-blind, 
placebo-controlled study comparing the safety and efficacy of oral GS-5245 with placebo in 
nonhospi[INVESTIGATOR_401524]-19, without risk factors for progression to severe 
disease regardless of vaccination status. 
Randomization will be stratified by [CONTACT_419801] (completed primary vaccination series: 
Yes or No).
Number of Participants Planned: Approximately 1900 participants may be enrolled. 
Target Population: Nonhospi[INVESTIGATOR_88492] ≥ 18 to < 65 years of age (at all sites), or 
aged ≥ 12 to < 18 years weighing ≥ 40 kg (US sites only after the first data monitoring 
committee [DMC] meeting has occurred), with COVID-19, without risk factors for 
progression to severe disease regardless of vaccination status.
Duration of Intervention: Participants will receive oral GS-5245 or placebo, twice daily, for 
5 days.
Diagnosis and Main Eligibility Criteria: 
Participants must meet all the following inclusion criteria to be eligible for participation in this 
study:
1) Aged ≥ 18 to < 65 years (at all sites), or aged ≥ 12 to < 18 years weighing ≥ 40 kg (US 
sites only, after the first DMC meeting has occurred) at screening.
2) Willing and able to provide written informed consent (and assent as applicable). For 
participants ≥ 12 and < 18 years of age, a parent or legal guardian willing and able to 
provide written informed consent prior to performing study procedures.
3) SARS-CoV-2 infection confirmed, ≤ [ADDRESS_529390], or an approved alternative assay. Serologic tests will not be 
accepted.
4) Willing and able to complete the COVID-[ADDRESS_529391] dose 
and daily throughout study period.
5) Initial onset of COVID-19 signs/symptoms ≤ 3 days before randomization with ≥ 2 of the 
following targeted symptoms, at moderate or higher severity, present at randomization:
a) Stuffy or runny nose. 
b) Sore throat. 
GS-5245
Protocol GS-US-611-6549 Final
[COMPANY_009] Sciences, Inc. Amendment 4
CONFIDENTIAL Page 12 12 December 2023c) Shortness of breath (difficulty breathing).
d) Cough.
e) Low energy or tiredness. 
f) Muscle or body aches. 
g) Headache.
h) Chills or shivering. 
i) Feeling hot or feverish.
6) Not currently hospi[INVESTIGATOR_419767].
Participants who meet any  of the following exclusion criteria are not eligible to be enrolled in 
this study:
1) Any risk factors for progression to severe disease.
2) Planning to receive a direct acting antiviral or monoclonal antibody against SARS-CoV-2 
for the treatment of COVID-19.
3) Received any approved, authorized, or investigational direct acting antiviral drug or 
monoclonal antibody against SARS-CoV-2 for the treatment of COVID-19 < 28 days or 
< 5 half-lives, whichever is longer, before randomization.
4) Received any convalescent COVID-19 plasma or other antibody-based anti-SARS-CoV-2 
prophylaxis at any time prior to study entry.
5) Received an approved, authorized, or investigational COVID-19 vaccine (including 
booster dose) < 120 days before randomization.
6) Self-reported COVID-19 diagnosis < 120 days before randomization.
7) Anticipated need for hospi[INVESTIGATOR_059] < 48 hours after randomization.
8) New oxygen requirement < 24 hours before randomization.
9) Known influenza, or any other suspected or confirmed concurrent active systemic 
infection other than COVID-19 that may interfere with the evaluation of response to the 
study drug. 
10) Known history of chronic liver disease, limited to cirrhosis, nonalcoholic steatohepatitis, 
alcoholic liver disease, and autoimmune hepatitis.
11) Undergoing dialysis, or known history of chronic kidney disease.
12) Known history of any of the following abnormal laboratory results < 6 months before 
randomization, unless confirmed as not meeting the exclusion criteria below, at screening:
a) ALT ≥ 5  upper limit of normal (ULN).
b) Bilirubin ≥ 2  ULN (≥ 3  ULN for participants with Gilbert’s syndrome).
c) CL cr < 60 mL/min or eGFR < 60 mL/min/1.73 m2.
GS-5245
Protocol GS-US-611-6549 Final
[COMPANY_009] Sciences, Inc. Amendment 4
CONFIDENTIAL Page 13 12 December 202313) Persistent symptoms from previous COVID-19 illness that may interfere with the 
evaluation of response to the study drug. 
14) Positive urine pregnancy test at screening.
15) Breastfeeding (nursing).
16) Unwilling to use protocol-mandated contraception.
17) Known hypersensitivity to the study drug, its metabolites, or formulation excipi[INVESTIGATOR_841].
18) Requirement for ongoing therapy with or prior use of any prohibited medications.
19) Any other factor, including inability to complete the patient-reported outcome (PRO) 
questionnaire for the primary endpoint, making the participant, in the opi[INVESTIGATOR_1070], unsuitable to participate in the study. 
20) Concurrent participation/enrollment in a separate therapeutic clinical study.
Study Procedures/Frequency: 
•Screening: within 24 hours of the baseline visit (screening visit can be the same as day as 
the baseline visit)
•Study treatment period: Day 1 (baseline) to Day 5
•Posttreatment follow-up: Up to [ADDRESS_529392], Dose, and Mode of Administration: GS-5245 350 mg (1 tablet) administered 
orally twice daily without regard to food with approximately 240 mL of water for 5 days.
Reference Therapy, Dose, and Mode of Administration: Placebo administered orally 
twice daily without regard to food with approximately 240 mL of water for 5 days.
Statistical Methods: 
A total sample size of approximately 1900 participants (assuming 90% are CoV-2 positive at 
baseline as confirmed by [CONTACT_2237]) provides approximately 87% power to detect a 
median difference of [ADDRESS_529393] ratio 
(HR) of 1.18 using a 2-sided significance level of 0.05, assuming the placebo group median 
time to symptom alleviation is 13 days. 
The median time to symptom alleviation and its 95% CI will be estimated by [CONTACT_419802]-Meier method. A stratified log-rank test with stratification factor included 
will be used to compare the treatment difference in time to COVID-19 symptom alleviation.
In addition, a Cox proportional hazards regression model will be used to estimate the HR and 
its 2-sided 95% CI. Stratification factor will be included as a covariate in the Cox proportional 
hazards model.
GS-5245
Protocol GS-US-611-6549 Final
[COMPANY_009] Sciences, Inc. Amendment 4
CONFIDENTIAL Page 14 12 December 2023An interim analysis of efficacy and futility is planned after approximately 50% of planned 
participants complete the Day [ADDRESS_529394] a review of safety and formal evaluation of futility and efficacy based on 
the unblinded interim analysis results.
GS-5245
Protocol GS-US-611-6549 Final
[COMPANY_009] Sciences, Inc. Amendment 4
CONFIDENTIAL Page 15 12 December 2023STUDY SCHEMA
Figure 1. Study Schema
COVID-19 = coronavirus disease 2019; D = Day; EOS = end of study; PCR = polymerase chain reaction
Day I COVlD· l9 ymptomQue stionnaire 
must be completed prior [ADDRESS_529395] dose .. D r:;i .;;;,, 0, 
v (±I ) 
12345678 
creeuing witlun 
2~hl:o 5~:~7.~:~o _. 
first dose DIO 
Visit 
(±2) D15 
Visit 
(±2) 
10 II 12 13 14 IS 16 17 18 
Smdy Period (Study Days) 
Treatmeu1 
Period: COV ID·l9 Symp1omQues1i ounaire 10 be comple1ed 
on ALL study days (Dl-29, D60 and D90) 
Days I lo 5 
• Day 29 visit will be in•pe rson and require a mid.turbinate nasal s wab collection for viral PCR 
if, any day after the Day 20 visit and p1ior to the Day 29 visit, the participant has: 
I mod erate or severe symptom repo11ed on the COVID• [ADDRESS_529396] EOS Visit 
22 23 24 2S 26 27 28 29 60 90 * 
8 • * ······················ • 
Oplional Obse1vational Real•\Vorld 
Subsudy: 1 2 month s from EDS 
Ju.pe rson 
Virtual 
In pmticipants who consent, real•world data may be 
followed out to 12 month s from end of study (US only) 
GS-5245
Protocol GS-US-611-6549 Final
[COMPANY_009] Sciences, Inc. Amendment 4
CONFIDENTIAL Page 16 12 December 2023STUDY PROCEDURES TABLE 
Table 1. Study Procedures Table
Study Visit Day 3 Day 5Day 
10Day 
15Day 
20 Day 29Day 
60EOS
Day 
90
Visit Window Screeninga, bBaseline
Day 1a± 1 dayc± 2 days + 5 days ± 7 daysEarly 
Discontinuation 
Visit
Visit Type In PersondIn 
Persone 
or 
VirtualfVirtualfIn Persond
Written informed consent (and assent as 
applicable)X
Medical historyh X
Document SARS-CoV-2 infection X
Complete physical examinationiX X X X
Symptom-directed physical examination X X
Height and weight X
Vital signsjX X X X X X X
COVID-19 Symptom QuestionnairekX X X X X X X X X X
WPAI + CIQ:COVID19 X X X X X X
PROMIS-29 X X X X X
Household contact[CONTACT_419803], coagulation, and hematology 
panelsm X X X X X X
Urine or serum pregnancy testsn X X X X
SARS-CoV-2 rapid antigen testoX X X X X X X
Mid-turbinate nasal swabpX X X X X X X X
SARS-CoV-2 serology X
CCI
GS-5245
Protocol GS-US-611-6549 Final
[COMPANY_009] Sciences, Inc. Amendment 4
CONFIDENTIAL Page 17 12 December 2023Study Visit Day 3 Day 5Day 
10Day 
15Day 
20 Day 29Day 
60EOS
Day 
90
Visit Window Screeninga, bBaseline
Day 1a± 1 dayc± 2 days + 5 days ± 7 daysEarly 
Discontinuation 
Visit
Visit Type In PersondIn 
Persone 
or 
VirtualfVirtualfIn Persond
Sparse PKqX X X
MAV information/oxygen supplementation 
requirements X X X X X X X X X X
Study drug dispensation X
Study drug dosing (GS-5245 or placebo)tX X X
Study drug bottle returnuX X X
Adverse events and concomitant medications X X X X X X X X X X X
COVID-19 = coronavirus disease 2019; EOS = end of study; MAV = medically attended visit; PK = pharmacokinetic(s); PROMIS-29 = Patient-Reported Outcomes Measurement 
Information System-29; SARS-CoV-2 = severe acute respi[INVESTIGATOR_6507] 2; WPAI + CIQ:COVID19 = Work Productivity and Activity Impairment + Classroom 
Impairment Questions: COVID-19 Infection
a Screening window is within 24 hours of the Day 1 visit. The Day 1 visit may occur on the same day as screening. If screening and the Day 1 visit are the same day, do not 
repeat physical examination and vital signs.
b Local screening laboratory tests including serum creatinine, creatinine clearance/estimated glomerular filtration rate, alanine aminotransferase, and bilirubin assessments at 
screening (prior to randomization) are not required unless deemed necessary by [CONTACT_295404]. Testing for influenza is also not required at screening. 
c Day 3 and Day 5 visits should be conducted on separate calendar days. 
d In-person visit is defined as a visit conducted at a medical facility or elsewhere by a health care provider (where permitted).
e Day 29 visit will be an in-person visit and require a nasal swab collection, only if any day after the Day 20 visit and prior to the Day 29 visit the participant has ≥ [ADDRESS_529397].
f Virtual visit is defined as an interaction with a health care professional using telephone or online-based interaction (eg, telehealth, webcast, video conferencing).
g Long COVID-19 sequelae will be assessed using linked data between clinical study participant and real-world data (RWD). 
h Medical history will include the date of first COVID-19 symptoms, overall COVID-19 symptoms, all COVID-19 vaccinations prior to screening, prior COVID-19 illness 
(including positive test type, month, and year), demographics, baseline characteristics, allergies, and all other relevant medical history. 
i A complete physical examination must include source documentation of general appearance and the following body systems: head, neck, and thyroid; eyes, ears, nose, throat, 
mouth, and tongue; chest (excluding breasts); respi[INVESTIGATOR_696]; cardiovascular; lymph nodes, abdomen; skin, hair, nails; musculoskeletal; and neurological. Urogenital and 
reproductive examination should only be completed if clinically indicated.
j Vital signs include heart rate, respi[INVESTIGATOR_697], temperature, oxygen saturation, and blood pressure. 
k The COVID-19 Symptom Questionnaire will be completed daily (at approximately the same time each day) from predose to Day [ADDRESS_529398] will be performed at the local laboratory for participants assigned female at birth and of childbea1ing potential. On Day 1, Day 15, and 
early discontinuation/un scheduled visits, these participant s will have a s enun pregnancy test via central laborato1y. At screening , a follicle-stimulating ho1mone test is 
required to confom the postrnenopausal state in participants younger than [ADDRESS_529399] doctuuentation of 
ovarian hormonal faihu·e , as described in Appendix 11.4. 
o Rapid antigen tests will be self-collected daily on all visit and non-visit days, up to Day 15, thereafter , on Days 17, 19, 21, 23, 25, 27, and 29. 
p The sample s will be used for SARS -Co V-2 reverse transcriptase-quan titative polymerase chain reaction (RT-qPCR) , potentia l infectiou s viral titer assessment, and potential 
resistance testing. Multiplex viral PCR will only be performed at Baseline/Day 1 visit. 
q Sparse PK samp les will be collected at Day 1 visit (0.75 hotu·s postdose and 2 hotu·s postdose), Day 3 visit (predose [within 1 hour before dosing] and 0.75 hours postdose), 
and Day 5 visit (predose [within 1 hour before dosing] and 0.75 hours postdose); ± 20% time window will be applied for all postdose time points. On Days 1, 3, and 5, one of 
the [ADDRESS_529400] be administered dtuing the in-erson visit. If a visit occtu·s on Da 6, PK sam !es should not be collec ted. 
r 
s e 1ca y attended visit information include s any interactions with health care profe ssionals other than study staff or designee s including hospi[INVESTIGATOR_1916] ; in-person 
emergency , urgen t, or primary care visits; or any other in-person visit attended by [CONTACT_4538] a health care profe ssional . The nattu·e and cause of the visit should be 
identified . Medically attended visit information and oxygen supplemen tation information should be collected through EOS/Day [ADDRESS_529401] rettun the study drng bottle on the Day 10 visit. 
CONFIDENTIAL Page 18 12 December 2023 
GS-5245
Protocol GS-US-611-6549 Final
[COMPANY_009] Sciences, Inc. Amendment 4
CONFIDENTIAL Page 19 12 December [ZIP_CODE]. INTRODUCTION
1.1. Background
Remdesivir (RDV; Veklury®) is approved for the treatment of COVID-19 in hospi[INVESTIGATOR_419768] (US), the European Union (EU), Japan, and other 
countries in pediatric and adult patients {VEKLURY 2022a, Veklury 2022b}. The broader utility 
of RDV for the nonhospi[INVESTIGATOR_419769]-CoV-2 is limited due to 
the intravenous (IV) route of administration; therefore, availability of more convenient oral 
treatment options is crucial for early therapy. Molnupi[INVESTIGATOR_42654] (LagevrioTM) and 
nirmatrelvir/ritonavir (PaxlovidTM) are the only 2 oral medications authorized for emergency use 
for the treatment of COVID-19 in the US. In the EU, nirmatrelvir/ritonavir is the only oral 
medication authorized for the treatment of COVID-19 in adults who do not require supplemental 
oxygen and who are at increased risk of progression to severe disease (conditional approval). 
Molnupi[INVESTIGATOR_419770], but the Committee for Medicinal Products for Human 
Use has issued advice on its use under Article 5(3) for the treatment of confirmed COVID-19 in 
adults who do not require supplemental oxygen and who are at increased risk of progression to 
severe COVID-19 in the EU. Molnupi[INVESTIGATOR_419771]-OUT 
study {Jayk Bernal 2022 }. There are curre ntly no approved therapi[INVESTIGATOR_419772] a standard 
risk of progression to severe disease but who may benefit from a shorter duration of illness as 
assessed by [CONTACT_23805], ability to return to usual health and activities, or duration of 
infectiousness. 
GS-5245 is a mono-5’-isobutyryl ester prodrug of GS-441524. Following oral administration, 
GS-5245 is extensively hydrolyzed presystemically to the parent nucleoside GS-441524, which 
can then enter cells where it is subsequently anabolized to the same active triphosphate 
metabolite (GS-443902) as RDV. GS-5245 has been developed with the intent to deliver 
consistent and high systemic exposures to GS-441524 following oral administration. At targeted 
therapeutic exposures with GS-5245, GS-441524 exposures are anticipated to be approximately 
14-fold higher as compared to exposures with RDV.
Availability of a highly effective oral treatment with a high barrier to resistance, similar to that of 
RDV, with minimal drug-drug interactions and with few tablets to take (ie, the dose of GS-5245 
selected for Phase 3 is one 350-mg tablet twice daily) has the potential to address a critical public 
health need in the ongoing COVID-[ADDRESS_529402] risk of progressing to severe COVID-19, that is anticipated to fulfill 
an unmet medical need.
GS-5245
Protocol GS-US-611-6549 Final
[COMPANY_009] Sciences, Inc. Amendment 4
CONFIDENTIAL Page 20 12 December [ZIP_CODE].2. Background on Study Interventions
1.2.1. GS-5245
[IP_ADDRESS]. General Information
GS-5245 is a mono-5’-isobutyryl ester prodrug of GS-441524, and following oral administration, 
is extensively hydrolyzed presystemically to yield the parent nucleoside of RDV, GS-441524. 
The prodrug GS-5245 was designed to specifically increase the oral bioavailability of 
GS-441524.
For further information on GS-5245, refer to the current investigator’s brochure (IB) for 
GS-5245, including information on the following:
•Toxicology
•Nonclinical pharmacology
•Nonclinical pharmacokinetics (PK)
Additional relevant nonclinical toxicology and clinical data are provided in Section [IP_ADDRESS].1 and 
Section [IP_ADDRESS].2.
[IP_ADDRESS].1. Toxicology
[IP_ADDRESS].1.1. Fertility Study
The objectives of the fertility study ([COMPANY_009] Study Number TX-611-2011) were to determine the 
potential adverse effects/disturbances in the reproductive process resulting from oral 
administration of GS-5245 to male and female Wistar Han rats from premating to conception and 
from conception to implantation. These included identification of deficits in estrous cycling, 
tubal transport, implantation, development of the preimplantation stages of the embryo in the 
female, and functional reproductive effects (alterations in libido and epi[INVESTIGATOR_419773]) in the male. Four groups (25 main study and 6 toxicokinetic [TK] phase/group) of 
male rats were administered GS-5245 by [CONTACT_419804] 0 (vehicle control), 125, 
250, or 500 mg/kg/day. Males were dosed for 14 days prior to mating and continuing through 
one day prior to euthanasia. Three groups (25 main and 6 TK/group) of female rats were dosed at 
0, 125, or 250 mg/kg/day. An additional 25 females were not dosed but used for breeding 
purposes only for the 500 mg/kg/day males. Females in the main study were dosed for 14 days 
prior to mating and continuing through Gestation Day (GD) 7. 
There were no GS-5245-related effects on male survival, clinical and macroscopic observations, 
body weights, body weight gains, food consumption, and organ weights at ≤ 250 mg/kg/day. 
Male reproductive performance (mating, fertility, and pregnancy indices and precoital intervals) 
and spermatogenic parameters were unaffected by [CONTACT_10827]-5245 administration at ≤ 500 mg/kg/day. 
There were no GS-5245-related effects on female survival or clinical observations at 
125 mg/kg/day or on premating and gestation body weights, body weight gains, food 
GS-5245
Protocol GS-US-611-6549 Final
[COMPANY_009] Sciences, Inc. Amendment 4
CONFIDENTIAL Page 21 12 December 2023consumption, estrous cycle length, reproductive performance, macroscopic findings, or organ 
weights at ≤ 250 mg/kg/day. Intrauterine survival was also not affected by [CONTACT_10827]-5245 
administration at any dose level.
Based on the lack of effects on reproductive performance and spermatogenic parameters, a dose 
level of 500 mg/kg/day (the highest dose level tested in males) was considered to be the 
no-observed-adverse-effect level (NOAEL) for male reproductive toxicity. Based on the lack of 
effects on female reproductive performance, estrous cyclicity, and intrauterine survival, the 
NOAEL for female reproductive toxicity and embryonic toxicity was considered to be 
250 mg/kg/day (the highest dose level tested in females). 
Based on mortality, clinical observations, body weight losses, and lower body weight gains and 
food consumption at 500 mg/kg/day in males, a dose level of 250 mg/kg/day was considered to 
be the NOAEL for male systemic toxicity. Based on mortality, clinical observations, body 
weight losses, and lower body weight gains and food consumption at 250 mg/kg/day in females, 
a dose level of 125 mg/kg/day was considered to be the NOAEL for female systemic toxicity. 
At the NOAELs for male and female reproductive toxicity, systemic GS-441524 exposures were 
approximately 5.7- and 6.7-fold higher than projected therapeutic exposure with oral GS-5245 
administration. 
[IP_ADDRESS].1.2. Phototoxicity
Results of a 3T3 neutral red uptake (NRU) test with GS-441524 using mouse fibroblasts showed 
that GS-441524 was not cytotoxic and did not display an half-maximal inhibitory concentration 
(IC 50) with or without ultraviolet radiation exposure, up to the highest soluble concentration 
tested (100 μg/mL) (TX-611-2026). Administration of GS-5245 is not considered to exhibit a 
photosafety risk.
[IP_ADDRESS].2. Clinical Studies of GS-5245 
[IP_ADDRESS].2.1. Study GS-US-611-[ADDRESS_529403] been administered GS-5245 or placebo at single doses 
of 100 mg (Cohort 1), 300 mg (Cohort 2), 900 mg (Cohort 3), and 1600 mg (Cohort 4) and 
multiple doses for 5 days at doses of 500 mg twice daily (Cohort 5) and 900 mg once daily 
(Cohort 6). Each cohort enrolled 8 participants who were randomized in a 3:1 ratio to receive 
oral GS-5245 or placebo. Preliminary PK and blinded safety data are available for all 
participants dosed in these 6 cohorts.
GS-5245
Protocol GS-US-611-6549 Final
[COMPANY_009] Sciences, Inc. Amendment 4
CONFIDENTIAL Page 22 12 December 2023Additionally, preliminary topline PK data are available from 22 participants (11 in each cohort) 
administered GS-5245 at a single dose of 500 mg under fasted (Cohort 8) and fed (Cohort 9) 
conditions. The formulation of GS-[ADDRESS_529404] 10 hours of overnight fasting. Administration in the fed state was defined as within 
5 minutes of completion of a high-fat/high-calorie meal (800 to 1000 kcal, 50% fat). 
Additionally, participants in both cohorts were restricted from food (4 hours after dose) and 
water consumption (1 hour before and 2 hours after dose) except for [ADDRESS_529405] participants were male (56.3%) and not Hispanic or Latino 
(87.5%). Approximately even proportions were White (45.8%) or Black or African American 
(41.7%). The median age was 31 years. Demographics were generally balanced between the 
groups.
Participant characteristics data for Cohorts 8 and 9 are not yet available. 
Safety Results
Overall, for Cohorts 1 to 6, administration of GS-5245 or placebo was generally safe and well 
tolerated. 
Treatment-emergent adverse events (AEs) were reported for 10 of 48 (20.8%) participants. Most 
AEs were Grade 1. There was 1 Grade 2 AE (vertigo not attributed to study drug), and no 
Grade 3 or higher AEs. There were no serious AEs (SAEs), AEs leading to premature 
discontinuation of study drug, or deaths. The only AEs reported in more than 1 participants were 
headache (3 of 48 participants [6.3%]), and contact [CONTACT_8748] (2 of 48 participants [4.2%]). The 
only AEs attributed to study drug was Grade 1 headache, which was reported for 2 of 
8 participants (25%) in Cohort 5 (500 mg twice daily for 5 days).
Overall, 25 of 48 participants (52.1%) had graded laboratory abnormalities. For each laboratory 
parameter, most abnormalities were reported for [ADDRESS_529406] 
frequently reported graded laboratory abnormality was decreased creatinine clearance (CL cr) 
which was reported for 13 of 48 participants (27.1%) overall and for 6 of 8 participants (75%) in 
Cohort 4 (1600 mg single dose). Creatinine clearance decreases were generally transient and 
returned to baseline levels. There was only 1 Grade 3 or higher laboratory abnormality: 
1 participant in Cohort 2 whose lipase was within normal limits on Days 2 and 5 (300 mg single 
dose) experienced a lipase elevation at Day 3.
There were no clinically relevant changes in vital signs, electrocardiogram (ECGs), or 
ophthalmologic examinations.
The safety profiles for Cohorts 8 and 9 are not yet available. In these cohorts, no SAEs, deaths, 
pregnancies, or study drug–related discontinuations were reported.
GS-5245
Protocol GS-US-611-6549 Final
[COMPANY_009] Sciences, Inc. Amendment 4
CONFIDENTIAL Page 23 12 December 2023Pharmacokinetic Results
Plasma:
Overall, GS-[ADDRESS_529407] absorption, linear PK, and similar terminal 
phases across 100 mg to 900 mg single doses tested. Less than dose-proportional increases in PK 
exposures were observed between 900 mg to 1600 mg (Table 2). Plasma exposures were 
exclusive to the GS-441524 metabolite; no detectable levels of GS-5245 prodrug were observed 
in the plasma at the 100 mg to 900 mg doses and transient exposure was observed at the 1600 mg 
dose. Multiple-dose PK was consistent with what was expected based on single-dose PK. 
Accumulation of GS-441524 after 5 days of dosing was consistent with plasma t 1/2 
(approximately 35% and 13% after twice-daily and once-daily dosing, respectively) ( Table 3).
Administration of GS-[ADDRESS_529408] on the overall plasma exposures of 
GS-441524; both C max and AUC inf were within the predefined no-effect bounds (0.60-1.67 for 
Cmax and 0.70-1.43 for AUC inf). The geometric least squares mean ratio (90% CI) of fed versus 
fasted for GS-441524 C max and AUC inf were 0.94 (0.73-1.22) and 1.13 (0.99-1.29), respectively. 
A high-fat meal slowed the rate of GS-5245 absorption, increasing GS-441524 T max from 0.75 to 
3.0 hours; this increase in T max is consistent with the anticipated delay in gastric emptying 
following a meal. The PK in Cohort 8 was consistent with data from previous cohorts, which 
received GS-5245 in fasted state. 
Urine: 
The GS-441524 metabolite renal clearance (CL r) was 150 to 180 mL/min, which is above the 
typi[INVESTIGATOR_419774] (eGFR, 120 mL/min) and consistent with historical 
data with IV RDV. No GS-[ADDRESS_529409] 6 to 12 hours after dosing with small 
incremental increases over the subsequent intervals (up to 96 hours). Approximately 40% to 45% 
of GS-[ADDRESS_529410] 24 hours postdose.
Peripheral Blood Mononuclear Cells (PBMCs):
Robust intracellular activation of GS-441524 to active triphosphate metabolite (GS-443902) was 
observed. Dose-proportional increases in the intracellular concentrations of GS-443902 were 
observed in PBMCs. Substantial accumulation of intracellular GS-443902 levels was observed 
after repeat dosing for 5 days (6-fold for twice daily and 3-fold for once daily; AUC 0-24h), which 
was consistent with the long half-life of this metabolite (Table 4).
GS-5245
Protocol GS-US-611-6549 Final
[COMPANY_009] Sciences, Inc. Amendment 4
CONFIDENTIAL Page 24 12 December 2023Table 2. GS-US-611-6248: Plasma Pharmacokinetic Parameters of GS-441524 in 
Single Ascending Dose Cohorts 1 Through 4
PK ParameteraGS-5245 100 mg 
(N = 6)GS-5245 300 mg 
(N = 6)GS-5245 900 mg 
(N = 6)GS-5245 1600 mg 
(N = 6)
GS-441524
Cmax (ng/mL) 570 (30.5) 1830 (32.6) 5980 (45.1) 7060 (24.7)
Tmax (h) 0.75 (0.56, 0.75) 0.75 (0.56, 1.5) 0.75 (0.75, 0.75) 1.50 (0.75, 1.88)
t1/2 (h) 6.3 (6.0, 6.7) 6.1 (5.0, 6.9) 6.5 (6.3, 6.9) 12.5 (7.1, 19.2)
AUC inf (h•ng/mL) 3820 (35.0) 10,900 (23.1) 37,200 (34.9) 48,100 (18.8)
%CV = percentage coefficient of variation; PK = pharmacokinetic(s); Q1 = first quartile; Q3 = third quartile
a Data presented as mean (%CV), except for T max and t 1/2 as median (Q1, Q3).
Table 3. GS-US-611-6248: Plasma Pharmacokinetic Parameters of GS-441524 in 
Multiple Ascending Dose Cohorts 5 and 6
PK ParameteraMultiple Dose
Day 1
(GS-5245 500 mg 
BID) 
(N = 6)Multiple Dose 
Day 5
(GS-5245 500 mg 
BID)
(N = 6)Multiple Dose 
Day 1
(GS-5245 900 mg 
QD)
(N = 6)Multiple Dose 
Day 5
(GS-5245 900 mg 
QD)
(N = 6)
GS-441524
Cmax (ng/mL) 3820 (32.7) 4620 (18.2) 6230 (14.5) 5180 (19.6)
Tmax (h) 0.75 (0.69-1.5) 0.75 (0.50-1.5) 0.75 (0.75-1.88) 1.5 (0.75, 3.0)
C24 (ng/mL) — 533 (17.0) — 158 (29.5)
t1/2 (h) — — — 10.3 (9.1, 19.0)
AUC 0-24h (h•ng/mL)b~31,800b ~43,000b 32,000 (11.5) 35,500 (12.3)
%CV = percentage coefficient of variation; BID = twice daily; PK = pharmacokinetic(s); Q1 = first quartile; Q3 = third quartile; 
QD = once daily
a Data are presented as mean (%CV), except for T max and t 1/2 as median (Q1, Q3).
b For BID dosing, AUC 0-24h = 2 ′ AUC 0-12h and does not account for the expected additional accumulation; Day 1 
AUC 0-12h = 15,900 (18.4); Day 5 AUC 0-12h = 21,500 (19.3).
GS-5245
Protocol GS-US-611-6549 Final
[COMPANY_009] Sciences, Inc. Amendment 4
CONFIDENTIAL Page 25 12 December 2023Table 4. GS-US-611-6248: PBMC Pharmacokinetic Parameters of GS-443902 in 
Multiple Ascending Dose Cohorts 5 and 6
PK ParameteraMultiple Dose 
Day 1
(GS-5245 500 mg 
BID)
(N = 6)Multiple Dose
Day 5
(GS-5245 500 mg 
BID)
(N = 6)Multiple Dose
Day 1
(GS-5245 900 mg 
QD)
(N = 6)Multiple Dose 
Day 5
(GS-5245 900 mg 
QD)
(N = 6)
GS-443902
Cmax (μM) 8.67 (41.4) 46.8 (50.0) 7.15 (56.5) 27.5 (44.1)
Tmax (h) 9.0 (6.0, 12.0) 12.0 (4.5, 12.0) 24.0 (6.0, 24.0) —
C24 (μM) — 46.0 (33.4) — 23.2 (65.6)
t1/2 (h) — — — 34.8 (28.9, 44.3)c
AUC 0-24h (h•μM)b~132b~852b104 (45.7) 348 (6.0)
%CV = percentage coefficient of variation; BID = twice daily; PBMC = peripheral blood mononuclear cell; 
PK = pharmacokinetic(s); Q1 = first quartile; Q3 = third quartile; QD = once daily
a Data are presented as mean (%CV), except for T max and t 1/2 as median (Q1, Q3). 
b For BID dosing, AUC 0-24h = 2 ′ AUC 0-12h and does not account for the expected additional accumulation; Day 1 
AUC 0-12h = 65.9 (39.8); Day 5 AUC 0-12h = 426 (48.4). 
c n = 3.
Conclusion
Overall, GS-5245 at single doses of 100 mg to 1600 mg and multiple doses of 500 mg twice 
daily or 900 mg once daily has been generally safe and well tolerated. Transient Grade 2 CL cr 
changes were predominantly observed in participants who received 1600 mg or placebo (6 of 
8 participants [75%]). There were no AEs associated with the laboratory findings. The only 
treatment-related AE reported in more than 1 participant was Grade 1 headache (n = 2).
Oral administration of GS-5245 resulted in high plasma exposures of the GS-441524 metabolite, 
with no detectable levels of prodrug itself. GS-5245 exhibited linear PK and similar terminal 
phases across 100 mg to 900 mg single doses tested. Less than proportional increases in AUC 
and C max were observed between the 900 and 1600 mg single doses tested. Terminal plasma t 1/[ADDRESS_529411] activation of 
GS-441524 to intracellular active triphosphate metabolite was observed and significant 
accumulation following twice-daily dosing. Administration of GS-5245 with high-fat meal 
decreased the rate but not the extent of GS-5245 absorption; thus, GS-[ADDRESS_529412] to food. 
[IP_ADDRESS].2.2. Study GS-US-611-6409
Study GS-US-611-6409 is an ongoing Phase 1 study to evaluate transporter and cytochrome 
P450 enzyme (CYP)-mediated drug-drug interactions (DDIs) between GS-5245 and probe drugs. 
This is an open-label, multicenter, fixed- (Cohorts 1, 2, 3, 5, and 7) or randomized-sequence 
(Cohorts 4 and 6) crossover study in healthy participants. The following interactions are planned 
to be evaluated in each cohort:
GS-5245
Protocol GS-US-611-6549 Final
[COMPANY_009] Sciences, Inc. Amendment 4
CONFIDENTIAL Page 26 12 December 2023•Cohorts 1 and 2: GS-5245 as a victim of strong P-glycoprotein (P-gp) inhibition using 
ritonavir and nirmatrelvir/ritonavir, respectively.
•Cohort 3: GS-[ADDRESS_529413] on a probe CYP3A substrate midazolam (MDZ).
•Cohort 4: GS-[ADDRESS_529414] on a probe P-gp substrate, dabigatran (DAB).
•Cohort 5: GS-[ADDRESS_529415] on a probe organic anion transporting polypeptide 
(OATP) 1B1/1B3 substrate, pi[INVESTIGATOR_2830] (PIT).
•Cohort 6: GS-[ADDRESS_529416] on a probe organic cation transporter (OCT) 1 substrate 
metformin (MET).
•Cohort 7: GS-5245 as a victim of gastric acid suppression using famotidine (FAM).
As of February 22, 2023, preliminary PK results are available in Cohorts 1 (n=15), 3 (n=19), 
5 (n=23), and 7 (n=14). For Cohort 1, participants received a single dose of GS-5245 350 mg on 
Day 1, followed by [CONTACT_364860] 100 mg BID on Days 4 to 8 with a single dose of GS-5245 350 mg 
coadministered on Day 6. For Cohort 3, participants received a single dose of MDZ 2.5 mg on 
Day 1 and a single dose of GS-5245 500 mg coadministered with a single dose of MDZ 2.5 mg 
on Day 3. For Cohort 5, participants received a single dose of PIT 2 mg and a single dose of 
GS-5245 500 mg coadministered with a single dose of PIT 2 mg on Day 4. For Cohort 7, 
participants received a single dose of GS-5245 350 mg on Day 1 and a single dose of FAM 
40 mg followed by a single dose of GS-5245 350 mg 2 hours after FAM on Day 4. All doses 
were oral and administered under fasting conditions. Cohort 2 was not enrolled based on 
emerging results from Cohort 1.
The safety profiles for Cohorts 1, 3, 5, and 7 are not yet available. In these cohorts, no SAEs, 
deaths, pregnancies, or study drug–related discontinuations were reported.
Pharmacokinetic Results
GS-5245 as a Perpetrator 
Cohort 3: Midazolam was used as a sensitive CYP3A substrate. Coadministration of MDZ with 
GS-5245 did not result in changes to plasma exposures of MDZ and its metabolite, 
1-hydroxymidazolam (1-OH-MDZ), as the geometric mean ratio (GMR) and 90% CI for C max, 
AUC last, and AUC inf were mostly within the predefined no-effect bounds of 80.0% to 125% 
(Table 5). 
GS-5245
Protocol GS-US-611-6549 Final
[COMPANY_009] Sciences, Inc. Amendment 4
CONFIDENTIAL Page 27 12 December 2023Table 5. GS-US-611-6409: Plasma Pharmacokinetic Parameters of Midazolam 
in Cohort 3
PK ParameteraMDZ 2.5 mg
(Reference, N = 19)MDZ 2.5 mg + GS-5245 
500 mg
(Test, N = 19)%GMR (90% CI)
Test/Reference
MDZ
Cmax (ng/mL) 10.0 (39.6) 11.5 (39.3) 114 (105, 124)
AUC last (h•ng/mL) 29.3 (50.5) 32.4 (51.2) 109 (103, 115)
AUC inf (h•ng/mL) 30.7 (50.7) 33.5 (50.6) 108 (102, 114)
1-OH-MDZ
Cmax (ng/mL) 3.75 (47.4) 4.27 (33.8) 117 (104, 132)
AUC last (h•ng/mL) 9.59 (44.5) 10.4 (27) 112 (103, 122)
AUC inf (h•ng/mL) 10.0 (30.8)b11.4 (25.9)c116 (107, 126)
%CV = percentage coefficient of variation; CI = confidence interval; GMR = geometric mean ratio; MDZ = midazolam; 
1-OH-MDZ = 1-hydroxymidazolam
a Data are presented as mean (%CV), unless otherwise specified.
b N = 13, terminal elimination slope was not reliably estimated for some profiles, ie, adjusted R2 < 0.8. 
c N = 18, terminal elimination slope was not reliably estimated for some profiles, ie, adjusted R2 < 0.8. 
Cohort 5: Pi[INVESTIGATOR_419775] a sensitive OATP1B1/1B3 substrate. Coadministration of PIT 
with GS-[ADDRESS_529417], and AUCinf were increased by 28% to 31% (Table 6). 
Table 6. GS-US-611-6409: Plasma Pharmacokinetic Parameters of Pi[INVESTIGATOR_419776] 5
PK ParameteraPIT 2.0 mg
(Reference, N = 23)PIT 2.0 mg + GS-5245 
500 mg
(Test, N = 20)%GMR (90% CI)
Test/Reference
PIT
Cmax (ng/mL) 24.7 (43.1) 31.1 (61.1) 130 (112, 151)
AUC last (h•ng/mL) 56.5 (47.7) 77.90 (68.1)b131 (121, 142)
AUC inf (h•ng/mL) 61.70 (45.5) 83.11 (66.2)b128 (118, 138)
%CV = percentage coefficient of variation; CI = confidence interval; GMR = geometric mean ratio; PIT = pi[INVESTIGATOR_2830]
a Data are presented as mean (%CV), unless otherwise specified.
b N = 18, terminal elimination slope was not reliably estimated for some profiles, ie, adjusted R2 < 0.8. 
GS-5245 as a Victim 
Cohort 1: Ritonavir was used as a strong P-gp inhibitor. Coadministration of GS-5245 with 
ritonavir did not result in changes to plasma exposures of GS-441524, as the GMR and 90% CI 
for C max, AUC last, and AUC inf were within the predefined no-effect bounds of 70.0% to 143% 
(Table 7).
GS-5245
Protocol GS-US-611-6549 Final
[COMPANY_009] Sciences, Inc. Amendment 4
CONFIDENTIAL Page 28 12 December 2023Table 7. GS-US-611-6409: Plasma Pharmacokinetic Parameters of GS-441524 
in Cohort 1
PK ParameteraGS-5245 350 mg
(Reference, N = 15)RTV 100 mg BID
+ GS-5245 350 mg
(Test, N = 15)%GMR (90% CI)
Test/Reference
GS-441524
Cmax (ng/mL) 2700 (52.2) 2700 (36.3) 104 (93.3, 117)
AUClast (h•ng/mL) 13,700 (27.5) 15,700 (20.6) 116 (108, 124)
AUCinf (h•ng/mL) 14,000 (26.8) 15,800 (20.4) 114 (106, 122)
%CV = percentage coefficient of variation; BID = twice daily; CI = confidence interval; GMR = geometric mean ratio; 
RTV = ritonavir
a Data are presented as mean (%CV), unless otherwise specified.
Cohort 7: Famotidine was used as a representative acid-reducing agent (ARA). The overall effect 
of increased gastric pH by [CONTACT_419805]-5245 was small. There was a 
32.5% decrease in the C max of GS-441524 with FAM, while the GMR and 90% CI for AUC last 
and AUC inf of GS-[ADDRESS_529418] bounds of 70.0% to 143% 
(Table 8). 
Table 8. GS-US-611-6409: Plasma Pharmacokinetic P
arameters of GS-441524 
in Cohort 7
PK ParameteraGS-5245 350 mg
(Reference, N = 14)GS-5245 350 mg + FAM 
40 mg
(Test, N = 13)b%GMR (90% CI)
Test/Reference
GS-441524
Cmax (ng/mL) 2670 (31.6) 1800 (29.5) 67.5 (55.3, 82.3)
AUC last (h•ng/mL) 13,900 (19.6) 10,500 (18.8) 76.6 (71.4, 82.3)
AUC inf (h•ng/mL) 14,000 (19.4) 10,700 (17.9) 77.0 (71.9, 82.5)
%CV = percentage coefficient of variation; CI = confidence interval; FAM = famotidine; GMR = geometric mean ratio
a Data are presented as mean (%CV), unless otherwise specified
b Data was not provided for 1 participant on Day 4
Conclusion
GS-5245 as a perpetrator: GS-5245 is not an inhibitor of CYP3A (as observed with MDZ) or a 
clinically relevant inhibitor of OATP1B1/1B3 (as observed with PIT). 
GS-5245 as a victim: There was no effect of P-gp inhibition (as observed with ritonavir) on 
plasma exposures of GS-441524. There was no clinically significant effect of increased gastric 
pH (as observed with FAM) on the plasma exposures of GS-441524; thus, GS-[ADDRESS_529419] antiviral 
treatment approved by [CONTACT_419806] {VEKLURY 2022a}, EU {Veklury 
2022b}, and multiple countries. More convenient options are needed for early intervention in the 
nonhospi[INVESTIGATOR_60992]-19 population.
The oral bioavailability of RDV is low based on nonclinical studies (< 1% in cynomolgus 
monkey) and unlikely to generate adequate human systemic exposure of RDV to drive antiviral 
activity against SARS-CoV-2 in the lung { Mackman 2021 }. GS-[ADDRESS_529420] a low composite rate of COVID-19-related 
hospi[INVESTIGATOR_30059], participants may benefit from effective antiviral therapy resulting in a 
shorter duration of illness as assessed by [CONTACT_23805], a quicker ability to return to usual health 
and activities, and a shortened duration of infectiousness. 
1.4. Rationale for Dose Selection of GS-5245 
The proposed dose for evaluation in this Phase 3 study is GS-5245 350 mg twice daily for 
5 days. This dose was selected based on the totality of available clinical and nonclinical data and 
with careful consideration of the overall risk-benefit profile. 
GS-5245 safety and PK were evaluated in a Phase 1 single and multiple ascending dose study 
(GS-US-611-6248) in healthy participants. Single GS-5245 doses up to 1600 mg and multiple 
doses of GS-5245 500 mg twice daily and GS-5245 900 mg once daily for 5 days were generally 
safe and well tolerated (most AEs were Grade 1 in severity). A graded laboratory abnormality of 
decreased CL cr was observed across all cohorts, although there was a disproportionately higher 
number of participants with decreased CL cr at the highest dose evaluated (single GS-5245 
1600 mg dose).
Following oral administration of GS-5245, the GS-441524 metabolite was the only circulating 
species. The plasma t 1/2 of this metabolite was approximately 6 hours, supporting twice-daily 
dosing. The twice-daily dosing regimen also provided higher daily exposure (AUC 0-24h), higher 
Ctau concentrations, and lower C max as compared with once-daily dosing (Section [IP_ADDRESS].2.1). 
GS-[ADDRESS_529421] intracellular formation of active metabolite was observed in the 
GS-US-611-6248 clinical study in PBMCs (eg, GS-5245 500 mg administered twice daily 
achieved GS-443902 levels comparable with IV RDV on Day 1 and exceeded those on later days 
by [CONTACT_3450] 4-fold). The intracellular formation of GS-443902 was dose proportional and 
significant accumulation was observed following twice-daily dosing (approximately 6-fold 
accumulation by [CONTACT_2006] 5).
GS-5245 showed therapeutic efficacy in multiple SARS-CoV-2 animal models (ie, mouse, ferret, 
and African green monkeys [AGMs]). Administration of GS-5245 to SARS-CoV-2–infected 
mice (10 mg/kg twice daily; AUC 0-24h = 10,500 h•ng/mL), ferrets (20 mg/kg once daily; 
AUC 0-24h = 28,500 h•ng/mL), and AGM (60 mg/kg once daily; AUC 0-24h = 25,700 h•ng/mL) for 
5 days resulted in a significant reduction of clinical signs of respi[INVESTIGATOR_3765], infectious virus 
titers in lungs, and genomic RNA compared with vehicle-treated animals. Similarly, in the AGM 
model, IV delivery of the parent nucleoside (20 mg/kg once daily; AUC 0-24h = 42,800 h•ng/mL) 
and oral administration of GS-621763, a tri-isobutyryl ester tool prodrug of GS-441524 
(60 mg/kg once daily; AUC 0-24h = 18,200 h•ng/mL; (120 mg/kg once daily; 
AUC 0-24h = 36,400 h•ng/mL) significantly reduced SARS-CoV-2 levels in the lower airways, as 
early as 1 to 2 days after infusion {Cox 2021, Pi[INVESTIGATOR_7929] 2022}.
GS-[ADDRESS_529422] risk for disease progression; this dosing regimen should 
provide systemic exposures of GS-441524 (predicted AUC 0-24h = 30,100 h•ng/mL) associated 
with efficacy in the SARS-CoV-2 animal models. Moreover, this dosing regimen allows for 
GS-441524 concentrations over the dosing interval to be predominantly maintained above the 
half-maximal effective concentration (EC 50) needed for SARS-CoV-2 viral inhibition in normal 
human bronchial epi[INVESTIGATOR_419777] (EC 50 = 713 ng/mL). This dosing regimen also provides a 
substantial exposure (C max) margin relative to the 1600 mg dose (approximately 2- to 3-fold) 
where potential drug-related effects on CL cr were observed. 
1.5. Risk/Benefit Assessment for the Study
Potential risks of a participant’s study involvement include unknown AEs, general risks 
associated with laboratory blood draws, and the associated pain and discomfort of phlebotomy.
Strategies to mitigate these risks include close monitoring of participants’ clinical statuses, 
laboratory values, and AEs. Parameters for discontinuation of the study drug due to AEs will be 
clearly defined and closely followed.
Participants in this study will receive either GS-[ADDRESS_529423] rapid assessment of the potential of 
GS-5245 to provide a treatment option for participants with COVID-19. Participant safety will 
be further protected by [CONTACT_419807] (DMC) that will evaluate 
safety data when the first [ADDRESS_529424] reached Day 29 or prematurely discontinued 
GS-5245
Protocol GS-US-611-6549 Final
[COMPANY_009] Sciences, Inc. Amendment 4
CONFIDENTIAL Page 31 12 December 2023from the study and when approximately 50% of planned participants have completed the Day [ADDRESS_529425] their origin in the Declaration of Helsinki and that are consistent with 
International Council for Harmonisation (ICH) Good Clinical Practice (GCP) and applicable 
regulatory requirements.
GS-5245
Protocol GS-US-611-6549 Final
[COMPANY_009] Sciences, Inc. Amendment 4
CONFIDENTIAL Page 32 12 December [ZIP_CODE]. OBJECTIVES AND ENDPOINTS
Primary Objectives Primary Endpoints
•To evaluate the efficacy of GS-5245 in reducing 
the duration of COVID-19 symptoms•Time to COVID-19 symptom alleviation by 
[CONTACT_2006] 29 
•To evaluate the safety and tolerability of GS-5245 
administered in nonhospi[INVESTIGATOR_419778]-19•Incidence of treatment-emergent AEs and 
laboratory abnormalities
•Incidence of SAEs and AEs leading to study drug 
discontinuation
Secondary Objectives Secondary Endpoints
•To assess the impact of GS-5245 on time to 
resolution of COVID-19 symptoms•Time to COVID-19 symptom resolution by 
[CONTACT_2006] 29
•To evaluate the impact of GS-5245 on moderate 
relapse of COVID-19 symptoms 
•To evaluate the efficacy of GS-5245 in reducing 
COVID-19–related medically attended visits 
(MAVs) or all-cause death•Proportion of participants with moderate relapse of 
COVID-19 symptoms by [CONTACT_2006] 29
•Proportion of participants with COVID-19–related 
MAVs or all-cause death by [CONTACT_2006] 29
•To evaluate the efficacy of GS-5245 in reducing 
COVID-19–related hospi[INVESTIGATOR_103151]-cause 
death•Proportion of participants with COVID-19–related 
hospi[INVESTIGATOR_419766]-cause death by [CONTACT_2006] 29
•To evaluate the antiviral activity of GS-5245 on 
SARS-CoV-2 nasal swab viral load at Day 5•Change from baseline in SARS-CoV-2 nasal swab 
viral load at Day 5
•To evaluate the effect of GS-5245 on duration of 
viral shedding •Time to antigen negativity
•To evaluate the effect of GS-5245 on viral rebound •Proportion of participants with viral antigen 
rebound
•To evaluate the plasma PK of GS-441524 
(metabolite of GS-5245) •Plasma concentrations and PK parameters AUC tau, 
Ctau, and C max of GS-441524, as available
•To evaluate the impact of GS-5245 on relapse of 
COVID-19 symptoms•Proportion of participants with relapse of 
COVID-19 symptoms by [CONTACT_2006] 29
GS-5245
Protocol GS-US-611-6549 Final
[COMPANY_009] Sciences, Inc. Amendment 4
CONFIDENTIAL Page 33 12 December 2023
CCI
GS-5245
Protocol GS-US-611-6549 Final
[COMPANY_009] Sciences, Inc. Amendment 4
CONFIDENTIAL Page 34 12 December [ZIP_CODE]. STUDY DESIGN
3.1. Study Design Overview
This Phase 3 study will be a global, randomized, double-blind, placebo-controlled study 
comparing the safety and efficacy of oral GS-5245 with placebo in nonhospi[INVESTIGATOR_419779]-19, without risk factors for progression to severe disease, regardless of vaccination 
status. Participants aged ≥ 12 and < 18 (weighing ≥ 40 kg) will be enrolled only in participating 
US sites, and after conclusion of the first planned DMC meeting.
Randomization will be stratified by [CONTACT_419801] (completed primary vaccination series: 
Yes or No).
An overview of the study design is shown in Figure 1.
3.2. Duration of Intervention
Participants will receive oral GS-5245 or placebo for 5 days.
3.3. Protocol-Specific Discontinuation Criteria
3.3.1. Criteria for Early Discontinuation for the Individual Participants 
[IP_ADDRESS]. Criteria for Early Discontinuation for the Individual Participants From Study 
Intervention
Study drug will be discontinued in the following instances:
•Any SAE suspected to be related to study drug.
•Any ≥ Grade 3 AE suspected to be related to study drug.
•An AE, or worsening of clinical condition requiring clinical intervention, that would, in the 
judgment of the investigator, affect assessments of clinical status to a significant degree.
•Any ≥ Grade 3 clinically significant laboratory abnormality (if confirmed by [CONTACT_15013]) 
suspected to be related to study drug.
•Baseline or on-treatment CL cr < 50 mL/min using the Cockcroft-Gault equation (for 
participants aged ≥ 18 to < 65 years of age) or eGFR < 50 mL/min/1.73 m2 using the Bedside 
Schwartz formula (for participants aged ≥ 12 to < 18 years of age). No confirmation repeat 
testing is required to meet this criterion. 
•Baseline or on-treatment alanine aminotransferase (ALT) ≥ 5  upper limit of normal (ULN).
GS-5245
Protocol GS-US-611-6549 Final
[COMPANY_009] Sciences, Inc. Amendment 4
CONFIDENTIAL Page 35 12 December 2023•Baseline or on-treatment bilirubin ≥ 2  ULN (≥ 3  ULN for participants with Gilbert’s 
syndrome).
•Unacceptable toxicity, as defined in Section 7.7, or toxicity that, in the judgment of the 
investigator, compromises the ability to continue study-specific procedures or is considered 
not to be in the participant’s best interest.
•Participant request to discontinue for any reason.
•Participant noncompliance.
•Pregnancy (refer to Appendix 11.4).
•Discontinuation of the study by [CONTACT_3211].
[IP_ADDRESS]. Criteria for Early Discontinuation for the Individual Participant From the Study 
The participant will be discontinued from the study regardless of whether treatment is ongoing in 
the following instances:
•Withdrawal of consent.
•Death.
3.3.2. Criteria for Early Discontinuation of the Study
The study will be discontinued in the following instances:
•Discontinuation of the study at the request of [COMPANY_009] Sciences ([COMPANY_009]) or a regulatory 
agency, institutional review board (IRB), or independent ethics committee (IEC).
3.3.3. Lost to Follow-up
Should the participant fail to attend a scheduled protocol-specific visit, sites will need to make at 
least [ADDRESS_529426] participant’s last observation (or visit) (LPLV).
3.5. Source Data
The source data for this study will be obtained from original records (eg, clinic notes, hospi[INVESTIGATOR_2553], participant charts), central laboratory, local laboratory, and specialty laboratory (for PK 
data), patient-reported outcomes (PROs), and interactive response technology (IRT).
GS-[ADDRESS_529427] meet all the following inclusion criteria to be eligible for participation in this 
study:
1) Aged ≥ 18 to < 65 years (at all sites), or aged ≥ 12 to < 18 years weighing ≥ 40 kg (US sites 
only, after the first DMC meeting has occurred) at screening.
2) Willing and able to provide written informed consent (and assent as applicable). For 
participants ≥ 12 and < 18 years of age, a parent or legal guardian willing and able to provide 
written informed consent prior to performing study procedures.
3) SARS-CoV-2 infection confirmed, ≤ 3 days before randomization, by [CONTACT_12036] (PCR), rapid antigen test, or an approved alternative assay. Serologic tests will not 
be accepted.
4) Willing and able to complete the COVID-[ADDRESS_529428] dose and 
daily throughout the study period.
5) Initial onset of COVID-19 signs/symptoms ≤ 3 days before randomization with ≥ 2 of the 
following targeted symptoms, at moderate or higher severity, present at randomization:
a) Stuffy or runny nose. 
b) Sore throat. 
c) Shortness of breath (difficulty breathing).
d) Cough.
e) Low energy or tiredness. 
f) Muscle or body aches. 
g) Headache.
GS-5245
Protocol GS-US-611-6549 Final
[COMPANY_009] Sciences, Inc. Amendment 4
CONFIDENTIAL Page 38 12 December 2023h) Chills or shivering. 
i) Feeling hot or feverish.
6) Not currently hospi[INVESTIGATOR_419767].
4.3. Exclusion Criteria
Participants who meet any  of the following exclusion criteria are not eligible to be enrolled in 
this study:
1) Any risk factors for progression to severe disease (Appendix 11.5).
2) Planning to receive a direct acting antiviral or monoclonal antibody against SARS-CoV-2 for 
the treatment of COVID-19.
3) Received any approved, authorized, or investigational direct acting antiviral drug or 
monoclonal antibody against SARS-CoV-2 for the treatment of COVID-19 < 28 days or 
< 5 half-lives, whichever is longer, before randomization.
4) Received any convalescent COVID-19 plasma or other antibody-based anti-SARS-CoV-2 
prophylaxis at any time prior to study entry.
5) Received an approved, authorized, or investigational COVID-19 vaccine (including booster 
dose) < 120 days before randomization.
6) Self-reported COVID-19 diagnosis < 120 days before randomization.
7) Anticipated need for hospi[INVESTIGATOR_059] < 48 hours after randomization.
8) New oxygen requirement < 24 hours before randomization.
9) Known influenza, or any other suspected or confirmed concurrent active systemic infection 
other than COVID-19 that may interfere with the evaluation of response to the study drug.
10) Known history of chronic liver disease, limited to cirrhosis, nonalcoholic steatohepatitis, 
alcoholic liver disease, and autoimmune hepatitis. 
11) Undergoing dialysis, or known history of chronic kidney disease 
12) Known history of any of the following abnormal laboratory results < 6 months before 
randomization, unless confirmed as not meeting the exclusion criteria below, at screening:
a) ALT ≥ 5  ULN.
b) Bilirubin ≥ 2  ULN (≥ 3  ULN for participants with Gilbert’s syndrome).
GS-5245
Protocol GS-US-611-6549 Final
[COMPANY_009] Sciences, Inc. Amendment 4
CONFIDENTIAL Page 39 12 December 2023c) CL cr < 60 mL/min or eGFR < 60 mL/min/1.73 m2.
13) Persistent symptoms from previous COVID-19 illness that may interfere with the evaluation 
of response to the study drug.
14) Positive urine pregnancy test at screening.
15) Breastfeeding (nursing).
16) Unwilling to use protocol-mandated contraception.
17) Known hypersensitivity to the study drug, its metabolites, or formulation excipi[INVESTIGATOR_841].
18) Requirement for ongoing therapy with or prior use of any prohibited medications (Table 9).
19) Any other factor, including inability to complete the PRO questionnaire for the primary 
endpoint, making the participant, in the opi[INVESTIGATOR_871], unsuitable to participate 
in the study. 
20) Concurrent participation/enrollment in a separate therapeutic clinical study. 
GS-5245
Protocol GS-US-611-6549 Final
[COMPANY_009] Sciences, Inc. Amendment 4
CONFIDENTIAL Page 40 12 December [ZIP_CODE]. STUDY INTERVENTIONS AND CONCOMITANT 
MEDICATIONS
5.1. Randomization, Blinding, and Treatment Code Access
5.1.1. Randomization
Participants who meet randomization eligibility criteria will be randomized in a 1:1 ratio to 
GS-5245 or placebo starting on Day 1 and assigned a participant number. Randomization will be 
stratified by [CONTACT_419801] (completed primary vaccination series: Yes or No).
5.1.2. Blinding
The study is a double-blinded study where participants, personnel directly involved in the 
conduct of study, and sponsor will not know the treatment participants received.
During the study, participants and all personnel directly involved in the conduct of the study will 
be blinded to treatment assignment. Specified personnel may be unblinded based on their study 
role. Study drug will be dispensed by [CONTACT_55775], or designee, in a blinded fashion to 
the participants. The Pharmacokinetics File Administrator, or designee, in Bioanalytical 
Operations and/or Clinical Data Management who facilitates the data transfer of PK files 
between [COMPANY_009] and vendors will remain unblinded. Individuals in Clinical Virology and 
Biomarker and Bioanalytical Operations performing sample selection for resistance analysis may 
be unblinded. Individuals in Clinical Packaging and Labeling or Clinical Supply Management 
who have an Unblinded Inventory Manager role in an IRT for purposes of study drug inventory 
management will remain unblinded. Individuals in Patient Safety who are responsible for safety 
signal detection, investigational new drug (IND) safety reporting, and/or expedited reporting of 
suspected unexpected serious adverse reactions may be unblinded to individual case data and/or 
group-level summaries. Regulatory Quality and Compliance personnel in Research and 
Development may also be unblinded for purposes of supporting Quality Assurance activities 
and/or regulatory agency inspections. Biostatisticians and programmers employed by [CONTACT_419808] (eg, outputs for DMC 
review, PK merge with clinical data). 
5.1.3. Planned Interim Internal Unblinding
Additionally, if the DMC recommends early study discontinuation due to efficacy/futility after 
reviewing the unblinded interim analysis results, a [COMPANY_009] internal unblinded team independent 
of the blinded study team may be assembled, to assess the safety, any available PK, and/or 
efficacy of GS-[ADDRESS_529429], and meeting schedule of the internal unblinded team will be 
documented as specified in [COMPANY_009] procedural documents.
5.1.4. Procedures for Breaking the Blind on Treatment Codes
In the event of a medical emergency where breaking the blind is required to provide medical care 
to the participant, the investigator may obtain the participant’s treatment assignment directly 
from the IRT for that participant. [COMPANY_009] recommends but does not require that the investigator 
contact [CONTACT_10848]. Treatment assignment should 
remain blinded unless that knowledge is necessary to determine participant emergency medical 
care. The rationale for unblinding must be clearly explained in source documentation along with 
the date on which the treatment assignment was obtained. The investigator is requested to 
contact [CONTACT_419809].
Blinding of study drug is critical to the integrity of this clinical study. Therefore, if a 
participant’s treatment assignment is disclosed to the investigator, the participant will have study 
drug discontinued. All participants will be followed until study completion unless consent to do 
so is specifically withdrawn by [CONTACT_2299].
5.2. Description and Handling 
5.2.1. Formulation
The GS-5245 350 mg strength tablets are oval shaped, debossed with “GSI” on one side and 
“5245” on the other side, and film-coated light yellow. In addition to the active ingredient, each 
film-coated tablet contains the following inactive ingredients: microcrystalline cellulose, 
crospovidone, magnesium stearate, macrogol polyvinyl alcohol graft copolymer, talc, titanium 
dioxide, glyceryl mono and dicaprylocaprate (glyceryl monocaprylocaprate type I), polyvinyl 
alcohol, and yellow iron oxide.
Placebo tablets are identical in size, shape, color, and appearance to the corresponding 
active-strength GS-5245 tablets. The placebo tablets contain commonly used excipi[INVESTIGATOR_840], 
including lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, magnesium 
stearate, macrogol polyvinyl alcohol graft copolymer, talc, titanium dioxide, glyceryl mono and 
dicaprylocaprate (glyceryl monocaprylocaprate type I), polyvinyl alcohol, and yellow iron oxide.
5.2.2. Packaging and Labeling
The GS-5245 350 mg tablets and corresponding placebo tablets are packaged in white, 
high-density polyethylene bottles. Each bottle contains 10 tablets and polyester packing material. 
Each bottle is enclosed with a white, continuous thread, child-resistant polypropylene screw cap 
with an induction-sealed and aluminum-faced liner.
Study drugs to be distributed to participating centers shall be labeled to meet applicable 
requirements of the US Food and Drug Administration (FDA), the EU Guideline to Good 
Manufacturing Practice - Annex 13 (Investigational Medicinal Products), the Japan-GCP 
(Ministerial Ordinance on Good Clinical Practice for Drugs), as applicable, and/or other local 
regulations, as applicable. 
GS-5245
Protocol GS-US-611-6549 Final
[COMPANY_009] Sciences, Inc. Amendment 4
CONFIDENTIAL Page 42 12 December [ZIP_CODE].2.3. Storage and Handling
GS-5245 and placebo tablets should be stored below 30 °C (86 °F). Storage conditions are 
specified on the label. Until dispensed to the participants, all bottles of study drugs should be 
stored in a securely locked area, accessible only to authorized site personnel. 
To ensure the stability and proper identification, study drugs should not be stored in a container 
other than the container in which they were supplied. Keep the bottle tightly closed to protect 
from moisture.
Consideration should be given to handling, preparation, and disposal through measures that 
minimize drug contact [CONTACT_10850]. Appropriate precautions should be followed to avoid direct 
eye contact [CONTACT_90265].
5.3. Dosage and Administration 
Participants randomized to the GS-5245 group will receive GS-5245 350 mg (1 tablet) 
administered orally twice daily without regard to food for [ADDRESS_529430] be discontinued, but the participant should 
continue in the study (See Section 6.4).
There are no restrictions on the symptomatic treatment of COVID-19 other than those indicated 
in Table 9. There are no restrictions on concomitant medications based on the potential for PK 
DDI with GS-5245.
Table 9. Prior and Concomitant Medications That Are Prohibited 
Medication Class Prohibited Medicationsa 
COVID-19 medicationsNirmatrelvir/ritonavir, molnupi[INVESTIGATOR_42654], ensitrelvir, IV RDV, monoclonal antibodies 
against COVID-19
COVID-19 = coronavirus disease 2019; IV = intravenous; RDV = remdesivir
a Concomitantly with GS-5245.
GS-5245
Protocol GS-US-611-6549 Final
[COMPANY_009] Sciences, Inc. Amendment 4
CONFIDENTIAL Page 43 12 December [ZIP_CODE].5. Accountability for Study Drug(s) 
The investigator is responsible for ensuring adequate accountability of all used and unused study 
drug bottles. This includes acknowledgment of receipt of each shipment of study drug (quantity 
and condition). All used and unused study drug bottles dispensed to participants must be returned 
to the site.
Each investigational site must keep accountability records to capture the following information:
•The date received, quantity, and condition of study drug bottles.
•The date, participant number, and the quantity of study drug bottles dispensed.
•The date, quantity of used, unused study drug bottles returned, and number of tablets within 
returned bottles along with the initials of the person recording the information.
5.5.1. Study Drug Return or Disposal
[COMPANY_009] recommends that used and unused study drugs, which includes bottles, be destroyed at the 
site. If the site has an appropriate standard operating procedure for drug destruction as 
determined by [CONTACT_10866], the site may destroy used (empty or partially empty) and unused study 
drug bottles in accordance with that site’s approved procedural documents. A copy of the site’s 
approved procedural document will be obtained for the electronic trial master file. If the study 
drug is destroyed at the site, the investigator must maintain accurate records for all study drugs 
destroyed. Records must show the identification and quantity of each unit destroyed, the method 
of destruction, and the person who disposed of the study drugs. Upon study completion, copi[INVESTIGATOR_419780]. Another copy will be provided 
to [COMPANY_009]. 
If the site does not have an appropriate standard operating procedure for study drug destruction, 
used and unused study drugs are to be sent to the designated disposal facility for destruction. The 
study monitor will provide instructions for return.
The study monitor will review study drug supplies and associated records at periodic intervals.
GS-[ADDRESS_529431] reseai·c h organizatio n. 
6.1. Informed Consent (and Assent as Applicable ) 
Written info1med consent (and assent as applicab le) must be obtained from each paiticipant , or 
with a pai·ent or legal guai·dian who can provide infonned consent, before initiatio n of any 
scree ning proced ure. After a paiticipant has provide d info1med consent (and assent as 
applicab le), the investigato r and other study perso nnel wi ll dete1min e if the p a1ticipant is eligible 
for paiticipatio n in the study (Sectio n 4.2 ). The investigator must use the m ost cunent IRB- or 
!EC-approved consent fonn for doclllllenting wr itten info1m ed consent. Each info1med consent 
(and assent as applicable) will be appropriately sign ed and dated by [CONTACT_419810] 's legally authorized representative and the perso n conduc ting the consent discussion, 
and also by [CONTACT_419811] l witness if required by [CONTACT_419812]. -
I 
I 
6.2. Screening , Participant Enrollment , and Treatment Assignment 
Paiticipants will be screened within 24 hours before emo llment in the study. Each paiticipant 
will be assigned a unique screening nlllllber using an IRT. Pa1ticipants meeting all of the 
inclusion criter ia and none of the exclusion cr iteria will return to the clinic within 24 hours for 
randomiza tion into the study. 
CONFIDENTIAL Page44 12 December 2023 
GS-5245
Protocol GS-US-611-6549 Final
[COMPANY_009] Sciences, Inc. Amendment 4
CONFIDENTIAL Page 45 12 December 2023Entry into screening does not guarantee enrollment into the study. [COMPANY_009], at its sole discretion, 
may suspend screening and/or enrollment at any site or study wide at any time.
It is the responsibility of the investigator to ensure that participants are eligible to participate in 
the study prior to enrollment and continue to remain eligible throughout the study.
Laboratory tests including serum creatinine, CL cr/eGFR, ALT, and bilirubin are not required at 
screening unless deemed necessary by [CONTACT_295404]. Testing for 
influenza is also not required at screening. Pregnancy testing is required at screening for 
participants assigned female at birth and of childbearing potential as described in Table 1.
Once written informed consent has been obtained, all screening and admission tests and 
assessments have been completed (including recording the dates of COVID-19 vaccinations), 
and study eligibility has been confirmed, participants will be randomized to receive GS-5245 or 
placebo on Day 1. Whenever possible, screening, randomization, and Day 1 dosing should occur 
on the same day. 
Participants will receive GS-5245 or placebo as described in Section 5.3.
6.3. Instructions for Study Procedures
An in-person visit is defined as a visit at a medical facility or elsewhere by a health care provider 
(where permitted). Virtual visit is defined as an online-based interaction (eg, telehealth, webcast, 
video conferencing).
6.3.1. Adverse Events
From the time informed consent is obtained through the first administration of study drug, record 
all SAEs, as well as any AEs related to protocol-required procedures, on the AE electronic case 
report form (eCRF). All other untoward medical occurrences observed during the screening 
period, including exacerbation or changes in medical history, are to be considered medical 
history. After study drug administration, report all AEs and SAEs. See Section 7 for additional 
details.
6.3.2. Safety Assessments
Safety will be evaluated throughout the study. Refer to Table 1 for a schedule of study 
procedures.
[IP_ADDRESS]. Physical Examination
Physical examinations conducted throughout the study during in-person visits will be a complete 
physical examination or a symptom-driven physical examination, as outlined in Table 1.
GS-[ADDRESS_529432] COVID-19 symptoms, overall COVID-19 
symptoms, exposure source, vaccination history, demographics, baseline characteristics, 
allergies, and all other medical history.
[IP_ADDRESS]. Vital Signs
Vital sign measurements include heart rate, respi[INVESTIGATOR_697], temperature, oxygen saturation, and 
blood pressure. Refer to Table 1 for vital signs collection time points.
[IP_ADDRESS]. Body Mass Index
Height and weight will be collected at screening for calculation of body mass index for inclusion 
criteria (See Appendix 11.5).
[IP_ADDRESS]. Clinical Laboratory Assessments
Blood sample collection for the following laboratory analyses ( Table 10) will be performed at 
the specified time points, where visits are conducted in person (Table 1). If a ≥ Grade 3 clinically 
significant laboratory abnormality needs to be repeated for confirmation, a local laboratory may 
be used if urgent results are needed for participant safety. However, a concurrent second set of 
blood samples should be drawn and sent to the central laboratory for proper documentation and 
data integrity. All other laboratory analyses performed on blood samples after screening should 
be collected and sent to the central laboratory.
•Chemistry 
eGFR according to:
Participants aged ≥ 18 to < 65 years: Cockcroft-Gault equation for CL cr {Cockcroft 
1976}. Weight at screening will be used for all CL cr calculations:
Men: (140 − age in years)  (weight in kg) = CL cr (mL/min)
72  (serum creatinine in mg/dL)
Women: (140 − age in years)  (weight in kg)   0.85 = CL cr (mL/min)
72  (serum creatinine in mg/dL)
Participants aged ≥ 12 and < 18 years:  Bedside Schwartz formula. Height at 
screening will be used for all calculations using the Schwartz formula:
Adolescents: (0.413  height in cm) = eGFR (mL/min/1.73 m2)
(serum creatinine in mg/dL)
•Hematology
•Coagulation 
GS-5245
Protocol GS-US-611-6549 Final
[COMPANY_009] Sciences, Inc. Amendment 4
CONFIDENTIAL Page 47 12 December 2023Table 10. Laboratory Analytes
Safety Laboratory Measurements 
Chemistry
(Serum or Plasma)Hematology Coagulation Other Laboratory 
Measurements
alkaline phosphatase, AST, 
ALT, total bilirubin, total 
protein, albumin, lactate 
dehydrogenase, creatine 
phosphokinase, bicarbonate, 
blood urea nitrogen, 
calcium, chloride, 
creatinine, glucose, lipase, 
magnesium, phosphorus, 
potassium, sodium, uric 
acid, creatinine clearancehemoglobin, 
hematocrit, red blood 
cell count, platelet 
count, white blood cell 
count with differential 
(absolute and 
percentage) including
neutrophils, monocytes, 
eosinophils, basophils, 
lymphocytesprothrombin time, 
partial 
thromboplastin 
time, international 
normalized ratioserum and urine pregnancy tests
and serum follicle-stimulating 
hormone in amenorrhoeic 
participants < 54 years of age
Pharmacokinetics
Anti-SARS-CoV-2 antibodies
ALT = alanine aminotransferase; AST = aspartate aminotransferase; SARS-CoV-2 = severe acute respi[INVESTIGATOR_18960] 2 
Refer to Table 1 for collection time points.
[IP_ADDRESS]. Concomitant Medications
Review of concomitant medications and protocol restrictions will occur at the times shown in 
Table 1. See Section 5.4 for more information about concomitant medications.
[IP_ADDRESS]. Medically Attended Visits
Review of MAV information will occur at the times shown in Table 1. Medically attended visits 
are any in-person interaction with health care professionals other than study staff or designees, 
including hospi[INVESTIGATOR_059]; in-person emergency, urgent, or primary care visits; or any other 
in-person visit attended by [CONTACT_4538] a health care professional.
[IP_ADDRESS]. Pregnancy Tests
Urine and/or serum pregnancy tests will be performed for participants assigned female at birth 
and of childbearing potential at the times shown in Table 1. At screening, a follicle-stimulating 
hormone test is required to confirm the postmenopausal state in participants younger than 
[ADDRESS_529433] documentation 
of ovarian hormonal failure, as described in Appendix 11.4. 
[IP_ADDRESS] Household Contacts
Information regarding number of household contacts and number of contacts diagnosed with 
COVID-[ADDRESS_529434] 
Rapid antigen tests will be perfonned by [CONTACT_31195]1ticipan ts on self-collected nasal swabs (anterior 
nares) to assess antigen positivity at the time points specified in Table 1. Results will be 
self-reported, with investigator confnmati on by [CONTACT_419813] , but not required. 
6.3.5. SARS-CoV-2 Serology 
Blood samples will be collected to assess anti-SARS-CoV-2 antibodies at the time point 
specified in Table 1. Any remainin g specime ns from blood sainples collected during the study 
will be stored and retain ed for possible future biomai·ker-related testing . These stored samp les 
may be used by [CONTACT_419814]·c h partners for retest ing anti-SARS-Co V-2 antibodies, for 
testing to leain more about how the study drng has worked, or for clinical laborato1y testing to 
provide additional safety data. At the conclusion of this study , these sainples may be retained in 
storage by [CONTACT_335248] a period of up to 15 years. 
Sainples collected for biomai·ker assessmen ts will be destroyed no later than 15 yeai·s after the 
end of the study or per country requirements (Sectio n 9.1 .4). 
6.3.6. 
[IP_ADDRESS]. 
[IP_ADDRESS].1. Clinical Virology 
Virology Testing 
Virology Samples to Address the Study Objectives 
Mid-turbinate nasal swab sainples will be used to assess SARS -CoV -2 viral load by [CONTACT_419815]·anscriptase-quantitative PCR (RT-qPCR). Once viral load testing is complete , the remnant 
sainples may be used to evaluate respi[INVESTIGATOR_141876]1y viral coinfect ion, SARS -CoV -2 infectious viral titer, 
and the emergence of viral resistance (by [CONTACT_7544] -CoV -2 sequenc ing and/or phenotypic testing) . 
[IP_ADDRESS].2. Virology Sample Storage 
Any remainin g specime ns from nasal swab sainples collected during the study will be stored and 
retained for possible future virology-related testing. These stored samples may be used by [CONTACT_419816]·c h partners for viral genotypi[INVESTIGATOR_007]/p henotypi[INVESTIGATOR_236689] , for 
retesting the amou nt of vims presen t in the sample, or for testing to leain more about how the 
CONFIDENTIAL Page48 12 December 2023 
GS-5245
Protocol GS-US-611-6549 Final
[COMPANY_009] Sciences, Inc. Amendment 4
CONFIDENTIAL Page 49 12 December 2023study drug has worked or clinical laboratory testing to provide additional safety data. At the 
conclusion of this study, these samples may be retained in storage by [CONTACT_335248] a period up to 
15 years or per country requirements.
6.3.7. Patient-Reported Outcomes 
The COVID-19 symptom questionnaire is required for the primary, secondary, and exploratory 
endpoints of the study. The ability to complete the COVID-19 symptom questionnaire is required 
for enrollment. The Work Productivity and Activity Impairment + Classroom Impairment 
Questions: COVID-19 Infection Specific (WPAI + CIQ: COVID19), and Patient-Reported 
Outcomes Measurement Information System (PROMIS-29) are required for this study. All PRO 
data will be collected electronically on a device. The participant should read and answer the 
questionnaire individually without external assistance. Patient-reported outcomes are outlined in 
Appendix 11.6.
Patient-reported outcomes will be required at the time points shown in Table 1. The following 
PROs will be utilized for this study:
[IP_ADDRESS]. COVID-19 Symptom Questionnaire 
The COVID-19 symptom questionnaire, to be completed daily at approximately the same time 
each day, was adapted from published FDA guidance on Assessing COVID-19-Related 
Symptoms in Outpatient Adult and Adolescent Subjects in Clinical Trials of Drugs and 
Biological Products for COVID-19 Prevention or Treatment Guidance for Industry {U. S. 
Department of Health & Human Services (DHHS) 2020}. It aims to capture the most clinically 
relevant symptoms of COVID-19 using an easily interpretable verbal response scale. 
[IP_ADDRESS].1. Procedures to Minimize Missing COVID-[ADDRESS_529435] to help participants remain compliant with questionnaire 
completion per protocol required time points:
•Participants will receive reminders/notifications at regular intervals every day to complete 
questionnaire.
•Site staff and the study monitor will review symptom questionnaire data completion reports 
to monitor compliance.
•Site staff will contact [CONTACT_419817] (or their close contact [CONTACT_419818], where feasible).
•Participants will be provided with a Value Sheet (if available) to highlight the significance of 
symptom questionnaire data and importance of participant compliance for the purposes of 
this study.
GS-5245 
Protocol GS-US-611 -654 9 
[COMPANY_009] Sciences , Inc. Final 
Amendment4 
[IP_ADDRESS]. Work Produ ctivity and Activity Impai1ment Questionnaire + Classroo m 
Impaiim ent Questions: COV ID-19 Infection 
The WPAI + CIQ: COVID -[ADDRESS_529436] 7 days. It has been validated to quanti fy work or education impaiiments for numerou s 
diseases {Reilly 1993} . 
[IP_ADDRESS]. Patient -Reported Outcomes Measurement Info1mation Syste m-29 
Up to 30% of people infected with SARS -Co V-[ADDRESS_529437] 1 symptom persisting longer than 
4 weeks {Azzo lini 2022 }. PROMI S-29 is a set of person-centered measures assess ing physical, 
mental, and social health {HealthMea sures 2022 } . The tool has been used to dete1mine the 
prevalence and characteristics of impaiiment after recove 1 y from acute COVID-19 {Roman o 
2022 }. --
-
CONFIDENTIAL Page 50 12 December 2023 
GS-5245
Protocol GS-US-611-6549 Final
[COMPANY_009] Sciences, Inc. Amendment 4
CONFIDENTIAL Page 51 12 December [ZIP_CODE].4. Assessments for Early Discontinuation From the Study 
If a participant discontinues study dosing (for example, as a result of an AE), every attempt 
should be made to keep the participant in the study and continue to perform the required 
study-related follow-up and procedures (see Section [IP_ADDRESS]). If this is not possible or acceptable 
to the pa
rticipant or investigator, the participant may be withdrawn from the study.
6.5. Assessments for End of Study
A participant who completes or discontinues from the study early will have an end of study visit 
(either Day 90 visit or early discontinuation visit, as applicable) for assessments and procedures 
specified in Table 1. 
6.6. Poststudy Care
The long-term care of the participants will remain the responsibility of their primary treating 
physicians. There is no provision for poststudy availability. 
6.7. Sample Storage
The stored biological samples may be used by [CONTACT_419819]. At the end of this 
study, these samples may be retained in storage by [CONTACT_335248] a period up to 15 years or per 
country requirements. 
Any remaining specimens from nasal swab samples collected during the study will be stored and 
retained for possible future virology-related testing. These stored samples may be used by [CONTACT_419820][INVESTIGATOR_007]/phenotypi[INVESTIGATOR_236689], for 
retesting the amount of virus present in the sample, or for testing to learn more about how the 
study drug has worked or clinical laboratory testing to provide additional safety data. At the 
conclusion of this study, these samples may be retained in storage by [CONTACT_335248] a period up to 
[ADDRESS_529438] a causal relationship with the treatment. An AE can therefore 
be any unfavorable and/or unintended sign, symptom, or disease temporally associated with the 
use of a study drug, whether or not the AE is considered related to the study drug. Adverse 
events may also include pretreatment or posttreatment complications that occur as a result of 
protocol-specified procedures or special situations (Section 7.1.3). 
An AE does not include the following:
•Medical or surgical procedures such as surgery, endoscopy, tooth extraction, or transfusion. 
The condition that led to the procedure may be an AE and must be reported.
•Preexisting diseases, conditions, or laboratory abnormalities present or detected before the 
screening visit that do not worsen.
•Situations where an untoward medical occurrence has not occurred (eg, hospi[INVESTIGATOR_10800], social and/or convenience admissions).
•Overdose without clinical sequelae (Section 7.1.3).
•Any medical condition or clinically significant laboratory abnormality with an onset date 
before the ICF is signed and not related to a protocol-associated procedure is not an AE but 
rather considered to be preexisting and should be documented as medical history.
Preexisting events that increase in severity or change in nature after study drug initiation or 
during or as a consequence of participation in the clinical study will also be considered AEs.
7.1.2. Serious Adverse Events
An SAE is defined as an event that, at any dose, results in the following:
•Death.
•A life-threatening situation (Note: The term “life-threatening” in the definition of “serious” 
refers to an event in which the participant was at risk of death at the time of the event; it does 
not refer to an event that hypothetically might have caused death if it were more severe.)
•In-patient hospi[INVESTIGATOR_1081].
GS-5245
Protocol GS-US-611-6549 Final
[COMPANY_009] Sciences, Inc. Amendment 4
CONFIDENTIAL Page 53 12 December 2023•Persistent or significant disability/incapacity.
•A congenital anomaly/birth defect.
•A medically important event or reaction: Such events may not be immediately life 
threatening or result in death or hospi[INVESTIGATOR_210134] [ADDRESS_529439] be exercised to determine whether such an event is reportable under 
expedited reporting rules. Examples of medically important events include intensive 
treatment in an emergency room or at home for allergic bronchospasm; blood dyscrasias or 
convulsions that do not result in hospi[INVESTIGATOR_059]; and development of drug dependency or 
drug abuse. 
7.1.3. Study Drugs and [COMPANY_009] Concomitant Medications Special Situation Reports
Special situation reports (SSRs) include all reports of medication error, abuse, misuse, overdose, 
occupational exposure, drug interactions, exposure via breastfeeding, unexpected benefit, 
transmission of infectious agents via the product, counterfeit of falsified medicine, and 
pregnancy regardless of an associated AE. 
Medication error is any unintentional error in the prescribing, dispensing, preparation for 
administration or administration of a study drug while the medication is in the control of a health 
care professional, participant, or consumer. Medication errors may be classified as a medication 
error without an AE, which includes situations of missed dose, medication error with an AE, 
intercepted medication error, or potential medication error.
Abuse is defined as persistent or sporadic intentional excessive use of a study drug by a 
participant.
Misuse is defined as any intentional and inappropriate use of a study drug that is not in 
accordance with the protocol instructions or the local prescribing information.
An overdose is defined as an accidental or intentional administration of a quantity of a study 
drug given per administration or cumulatively that is above the maximum recommended dose as 
per protocol or in the product labeling (as it applies to the daily dose of the participant in 
question). In cases of a discrepancy in drug accountability, overdose will be established only 
when it is clear that the participant has taken the excess dose(s). Overdose cannot be established 
when the participant cannot account for the discrepancy, except in cases in which the 
investigator has reason to suspect that the participant has taken the additional dose(s).
Occupational exposure is defined as exposure to a study drug as a result of one’s professional or 
nonprofessional occupation.
Drug interaction is defined as any drug/drug, drug/food, or drug/alcohol, or drug/device 
interaction.
GS-[ADDRESS_529440] where the results are judged to 
be desirable and beneficial. 
Transmission of infectious agents is defined as any suspected transmission of an infected agent 
through a [COMPANY_009] study drug.
Counterfeit or falsified medicine is defined as any study drug with a false representation of (a) its 
identity, (b) its source, or (c) its history.
7.2. Assessment of Adverse Events and Serious Adverse Events
The investigator or qualified subinvestigator is responsible for assessing AEs and SAEs for 
causality and severity, and for final review and confirmation of accuracy of event information 
and assessments.
7.2.1. Assessment of Causality for Study Drugs and Procedures
The investigator or qualified subinvestigator is responsible for assessing the relationship for each 
study drug using clinical judgment and the following considerations:
•No: Evidence exists that the AE has an etiology other than the study drug. For SAEs, an 
alternative causality must be provided (eg, preexisting condition, underlying disease, 
intercurrent illness, concomitant medication).
•Yes: There is reasonable possibility that the AE may have been caused by [CONTACT_5257].
It should be emphasized that ineffective treatment should not be considered as causally related in 
the context of AE reporting. 
The relationship to study procedures (eg, invasive procedures such as venipuncture or biopsy) 
should be assessed using the following considerations:
•No: Evidence exists that the AE has an etiology other than the study procedure.
•Yes: The AE occurred as a result of protocol procedures (eg, venipuncture).
7.2.2. Assessment of Severity 
The severity of AEs will be graded using the Division of AIDS (DAIDS) Table for Grading the 
Severity of Adult and Pediatric Adverse Events, Version 2.1 (corrected, July 2017) available at 
https://rsc.niaid.nih.gov/sites/default/files/daidsgradingcorrectedv21.pdf (Section 8.6.3). For each 
epi[INVESTIGATOR_1865], the highest grade attained should be reported as defined in the grading scale. 
GS-[ADDRESS_529441] be 
reported on the applicable eCRFs: all SAEs and any AEs that are related to protocol-required 
procedures.
7.3.2. Adverse Events
Following initiation of study drug, collect all AEs, regardless of cause or relationship, until 
[ADDRESS_529442] consents to 
participate in the study (ie, signing the ICF) and throughout the duration of the study, including 
the posttreatment follow-up visit, must be reported on the applicable eCRFs and to [COMPANY_009] 
Patient Safety as instructed below in this section. This also includes any SAEs resulting from 
protocol-associated procedures performed after the ICF is signed.
Investigators are not obligated to actively seek SAEs after the protocol-defined follow-up period; 
however, if the investigator learns of any SAEs that occur after the protocol-defined follow-up 
period has concluded and the event is deemed relevant to the use of study drug, the investigator 
should promptly document and report the event to [COMPANY_009] Patient Safety.
Instructions for reporting SAEs are described in Section 7.4.1.
7.3.4. Study Drug Special Situation Reports
All study drug SSRs that occur from study drug initiation and throughout the duration of the 
study, including the posttreatment follow-up visit, must be reported to [COMPANY_009] Patient Safety 
(Section 7.4.2). Adverse events and SAEs resulting from SSRs must be reported in accordance 
with the AE and SAE reporting guidance (Section 7.3).
7.3.5. Concomitant Medications Reports
[IP_ADDRESS]. [COMPANY_009] Concomitant Medications Special Situation Report
Special situation reports involving a [COMPANY_009] concomitant medication (not considered study drug), 
that occur after the participant first consents to participate in the study (ie, signing of the ICF) 
and throughout the duration of the study, including the posttreatment follow-up visit, must be 
reported to [COMPANY_009] Patient Safety utilizing the paper SSR (Section 7.4.2).
GS-5245
Protocol GS-US-611-6549 Final
[COMPANY_009] Sciences, Inc. Amendment 4
CONFIDENTIAL Page 56 12 December [ZIP_CODE].3.5.2. Non-[COMPANY_009] Concomitant Medications Report
Special situations involving non-[COMPANY_009] concomitant medications do not need to be reported on 
the SSR form; however, for special situations that result in AEs because of a non-[COMPANY_009] 
concomitant medication, the AE should be reported on the AE eCRF. 
Any inappropriate use of concomitant medications prohibited by [CONTACT_10857] “misuse,” but may be more appropriately documented as a protocol deviation.
All clinical sequelae in relation to these SSRs will be reported as AEs or SAEs at the same time 
using the AE eCRF and/or the SAE eCRF. Details of the symptoms and signs, clinical 
management, and outcome will be reported, when available.
7.4. Reporting Process for Serious Adverse Events and Special Situation Reports
7.4.1. Serious Adverse Event Reporting Process
For fatal or life-threatening events, copi[INVESTIGATOR_3103], autopsy reports, and other 
documents are also to be transmitted by [CONTACT_82234]. 
Transmission of such documents should occur without personal participant identification, 
maintaining the traceability of a document to the participant identifiers.
Additional information may be requested to ensure the timely completion of accurate safety 
reports.
Any medications necessary for treatment of the SAE must be recorded onto the concomitant 
medication section of the participant’s eCRF and the SAE narrative section of the Safety Report 
Form eCRF.
[IP_ADDRESS]. Electronic Serious Adverse Event Reporting Process 
Site personnel will record all SAE data on the applicable eCRFs and from there transmit the SAE 
information to [COMPANY_009] Patient Safety within 24 hours of the investigator’s knowledge of the event 
from the time of the ICF signature [CONTACT_210194], including the 
protocol-required posttreatment follow-up period. 
If for any reason it is not possible to record and transmit the SAE information electronically, 
record the SAE on the paper SAE reporting form and transmit within 24 hours to:
[COMPANY_009] Patient Safety:
Email: [EMAIL_201]
or
Fax: [PHONE_4399]
GS-[ADDRESS_529443] be 
transcribed as soon as possible on the applicable eCRFs and transmitted to [COMPANY_009] Patient Safety.
7.4.2. Special Situation Reporting Process
[IP_ADDRESS]. Electronic Special Situation Reporting Process for Study Drug 
Site personnel will record all SSR data on the applicable eCRFs and from there transmit the SSR 
information within 24 hours of the investigator’s knowledge to [COMPANY_009] Patient Safety from study 
drug initiation throughout the duration of the study, including the protocol-required 
posttreatment follow-up period. 
If for any reason it is not possible to record and transmit the SSR information electronically, 
record the SSR on the paper SSR form and transmit within 24 hours to:
[COMPANY_009] Patient Safety 
Email: [EMAIL_201] 
or
Fax: [PHONE_4399] 
If an SSR has been reported via a paper form because the eCRF database has been locked, no 
further action is necessary. If the database is not locked, any SSR reported via paper must be 
transcribed as soon as possible on the applicable eCRFs and transmitted to [COMPANY_009] Patient Safety.
See Section [IP_ADDRESS] for instructions on reporting special situations with [COMPANY_009] concomitant 
medications. 
[IP_ADDRESS]. Reporting Process for [COMPANY_009] Concomitant Medications
Special situations that involve [COMPANY_009] concomitant medications that are not considered study 
drug must be reported within 24 hours of the investigator’s knowledge of the event to [COMPANY_009] 
Patient Safety utilizing the paper SSR form and transmitted to:
[COMPANY_009] Patient Safety:
Email: [EMAIL_201]
or
Fax: [PHONE_4399]
Any inappropriate use of concomitant medications prohibited by [CONTACT_10857] “misuse,” but may be more appropriately documented as a protocol deviation.
Special situations involving non-[COMPANY_009] concomitant medications do not need to be reported on 
the SSR form; however, special situations that result in AEs because of a non-[COMPANY_009] 
concomitant medication, must be reported on the AE eCRF.
GS-[ADDRESS_529444] study drug dose in participants and/or pregnancies in partners resulting 
from exposure to sperm from a participant in the study period in which contraceptive measures 
are needed. Pregnancies should be reported to [COMPANY_009] Patient Safety within [ADDRESS_529445] details for transmitting the 
pregnancy report form are as follows:
[COMPANY_009] Patient Safety:
Email: [EMAIL_201]
or
Fax: [PHONE_4399] 
The pregnancy itself is not considered an AE, nor is an induced elective abortion to terminate a 
pregnancy without medical reasons.
All other premature terminations of pregnancy (eg, a spontaneous abortion, an induced 
therapeutic abortion because of complications or other medical reasons) must be reported within 
[ADDRESS_529446] be reported to the [COMPANY_009] Patient Safety. However, if a pregnancy-related SAE occurs in a 
partner, it should not be captured in the eCRF, but reported via the paper pregnancy outcome 
report form.
The participant should receive appropriate monitoring and care until the conclusion of the 
pregnancy. The outcome of the pregnancy/partner pregnancy should be reported to [COMPANY_009] 
Patient Safety using the pregnancy outcome report form. If the end of the pregnancy/partner 
pregnancy occurs after the study has been completed, the outcome should be reported directly to:
[COMPANY_009] Patient Safety:
Email: [EMAIL_201]
or
Fax: [PHONE_4399] 
Refer to Appendix 11.4 for Pregnancy Precautions, Definition for Childbearing Potential, and 
Contraceptive Requirements.
GS-5245 
Protoco l GS-US-611 -654 9 
[COMPANY_009] Sciences , Inc. 
7.5. [COMPANY_009] Reporting Requirement s Final 
Amendment4 
Depending on relevant local legislatio n or regulati ons, includin g the applicable US FDA CFR , 
the EU Regulation 536/2014 and relevant updates , and other countiy -speci fic legislatio n or 
regulations , [COMPANY_009] may be required to expedite to worldwide regulato1y agencies the repo1ts of 
SAEs , which m ay be in the fonn of line listings, serious ad verse drng reactions, or su spected 
unexpected serious ad verse reactions. In accor dance with the EU Regulation 536/2014 , [COMPANY_009] or 
a speci fied designee will notify worldwide regulato1 y agencies and the relevant IEC in concerned 
Member States of applicable suspected unexpec ted serious adverse reactions as outlined in 
cmTent regulations. 
Assess ment of expectedness for SAEs will be determined by [CONTACT_419821]. 
All investigators will receive a safety letter notifying them of relevant suspected unexpecte d 
serious adve rse reaction reports associated with any study diug. The investigato r sho uld notify 
the IRB/IEC of suspected unexpected serious ad verse reaction repo1t s as soon as is practical, 
where this is requir ed by [CONTACT_353890]1y agencies , and in accordance with the local institutional 
policy. -
7.6. Clinical Laboratory Abnormalities and Other Abnormal Assessments as 
Adverse Events or Serious Adverse Events 
Laborato1y abnonnalities without clinical signi ficance are n ot to be recorded as AEs or SAEs . 
However , laborato 1 y abnonnalities ( eg, clinical cheini stiy , hematology, urinalysis) that require 
medica l or surgical interve ntion or lead to study diug inte1n1pti on, m odificatio n, or 
discontinuation must be recorded as an AE, as well as an SAE, if applicable. In addition, 
laborato 1 y or other abnonnal assessments (eg, ECG, x-rays, vital signs) that are associate d with 
signs and/or symptoms must be recorded as an AE or SAE if they meet the definition of an AE 
or SAE as descr ibed in Sectio ns 7 .1.1 and 7 .1.2. If the laborato1y ab nonnality is part of a 
syndi·ome, record the syndi·ome or diagnosis ( eg, aneinia) , not the laborato1y result (ie, decreased 
hemoglobin). 
CONFIDENTIAL Page 59 12 December 2023 
GS-5245
Protocol GS-US-611-6549 Final
[COMPANY_009] Sciences, Inc. Amendment 4
CONFIDENTIAL Page 60 12 December 2023Severity should be recorded and graded according to the DAIDS Table for Grading the Severity 
of Adult and Pediatric Adverse Events, Version 2.1 (corrected, July 2017). For AEs associated 
with laboratory abnormalities, the event should be graded on the basis of the clinical severity in 
the context of the underlying conditions; this may or may not be in agreement with the grading 
of the laboratory abnormality. The DAIDS scale is available at:
https://rsc.niaid.nih.gov/sites/default/files/daidsgradingcorrectedv21.pdf
7.7. Toxicity Management 
7.7.1. GS-5245
All clinical and clinically significant laboratory toxicities will be managed according to the 
guidelines described below.
The [COMPANY_009] medical monitor should be consulted prior to study drug discontinuation when 
medically feasible. Before discontinuation of study drug for AEs or laboratory abnormalities, an 
assessment of the participant’s medical situation should be made by [CONTACT_093].
[IP_ADDRESS]. Laboratory Events Meeting Discontinuation Criteria
Laboratory events meeting discontinuation criteria are discussed in Section [IP_ADDRESS].
[IP_ADDRESS]. Grades 1 and 2 Laboratory Abnormality or Clinical Event
Continue study drug at the discretion of the investigator.
[IP_ADDRESS]. Grade [ADDRESS_529447] a CL cr < 50 mL/min by [CONTACT_3158]-Gault equation (for 
participants ≥ 18 to < 65 years of age) or eGFR < 50 mL/min/1.73 m2 by [CONTACT_419822] (for participants ≥ 12 and < 18 years of age) will be discontinued from study drug 
whether considered related to the study drug or not (refer to Section [IP_ADDRESS]). No confirmation 
repeat testing is required to meet this criterion.
Recurrence of laboratory abnormalities considered unrelated to study drug may not require 
permanent discontinuation but requires discussion with the [COMPANY_009] medical monitor.
GS-[ADDRESS_529448]. A clinically significant Grade 4 laboratory 
abnormality that is not confirmed by [CONTACT_419823].
Study drug may be continued without dose interruption for a clinically nonsignificant Grade 4 
laboratory abnormality (eg, Grade 4 creatine kinase elevation after strenuous exercise or 
triglyceride elevation that is nonfasting or that can be medically managed) or a clinical event 
considered unrelated to study drug.
Treatment-emergent toxicities will be noted by [CONTACT_122036], and the appropriate course of action will be discussed and decided. 
Whether or not considered treatment-related, all participants experiencing AEs must be 
monitored periodically until symptoms subside, any abnormal laboratory values have resolved or 
returned to baseline levels or they are considered irreversible, or until there is a satisfactory 
explanation for the changes observed.
Any questions regarding toxicity management should be directed to the [COMPANY_009] medical monitor.
GS-5245
Protocol GS-US-611-6549 Final
[COMPANY_009] Sciences, Inc. Amendment 4
CONFIDENTIAL Page 62 12 December [ZIP_CODE]. STATISTICAL CONSIDERATIONS
Details of the statistical methods will be provided in the statistical analysis plan, including any 
deviations from the original statistical analyses planned.
8.1. Analysis Objectives and Endpoints
Objectives and endpoints are listed in Section 2.
8.1.1. Primary Endpoint
The primary endpoint is the time (days) to COVID-19 symptom alleviation by [CONTACT_2006] 29 on the 
targeted symptoms measured via the COVID-19 symptom questionnaire. Symptom alleviation is 
defined as follows: all targeted symptoms scored moderate or severe at baseline are scored as 
mild or none for at least [ADDRESS_529449] 48 consecutive hours; the first day of the 48 consecutive 
hours will be considered the symptom alleviation date. 
Targeted symptoms are those listed below:
•Stuffy or runny nose.
•Sore throat. 
•Shortness of breath (difficulty breathing).
•Cough.
•Low energy or tiredness.
•Muscle or body aches.
•Headache.
•Chills or shivering. 
•Feeling hot or feverish.
8.1.2. Secondary Efficacy Endpoints
[IP_ADDRESS]. Key Secondary Efficacy Endpoints
The alpha-controlled secondary endpoints include the following:
•Time to COVID-[ADDRESS_529450] day of the 48 consecutive hours will be considered the date of 
symptom resolution. The time to COVID-19 symptom resolution is the time (days) from the first 
dose date to the date of symptom resolution.
•Proportion of participants with moderate relapse of COVID-[ADDRESS_529451] 2 consecutive diary entries 
(regardless of missing entries in between) where there is any symptom (regardless of severity) 
after achieving short symptom recovery, or if a participant is hospi[INVESTIGATOR_191544]-[ADDRESS_529452] 2 consecutive diary entries 
(regardless of missing entries in between) where all targeted symptoms are absent. If a 
hospi[INVESTIGATOR_53763]-[ADDRESS_529453] 2 mild symptoms OR a hospi[INVESTIGATOR_53763]-19, observed on a day 
during COVID-19 symptom relapse (first day of symptom relapse to Day 28). 
•Proportion of participants with COVID-19–related MAVs or all-cause death by [CONTACT_2006] 29. 
Medically attended visits are defined as any interactions with health care professionals other than 
study staff or designees including hospi[INVESTIGATOR_059]; in-person emergency, urgent, or primary care 
visits; or any other in-person visit attended by [CONTACT_4538] a health care professional. The 
nature and cause of the visit should be identified.
•Proportion of participants with COVID-19–related hospi[INVESTIGATOR_419766]-cause death by 
[CONTACT_2006] 29.
COVID-19–related hospi[INVESTIGATOR_31561] ≥ 24 hours of acute care for a reason related to 
COVID-19, in a hospi[INVESTIGATOR_419781], including emergency rooms or temporary 
facilities instituted to address medical needs of those with COVID-19. This includes specialized 
acute medical care units within an assisted living facility or nursing home. This does not include 
hospi[INVESTIGATOR_295363]/or clinical trial execution. The date and 
duration of hospi[INVESTIGATOR_063], and primary reason for hospi[INVESTIGATOR_059] (including if the 
hospi[INVESTIGATOR_419782]-19) will be recorded. 
8.2. Planned Analyses
8.2.1. Interim Analysis 
Before the final analysis, interim analyses will be conducted, and the analyses may be submitted 
to regulatory agencies to seek guidance for the overall clinical development program.
GS-5245
Protocol GS-US-611-6549 Final
[COMPANY_009] Sciences, Inc. Amendment 4
CONFIDENTIAL Page 64 12 December [ZIP_CODE].2.1.1. Data Monitoring Committee Analysis 
A planned interim analysis of safety and efficacy is planned after approximately 50% of the 
planned participants reach Day 29 or prematurely discontinue from the study (see Section 8.10). 
8.2.2. Primary Analysis
The unblinded primary analysis will be conducted after all participants have completed the 
Day [ADDRESS_529454] 
been cleaned and finalized. 
8.3. Analysis Conventions
8.3.1. Analysis Sets
[IP_ADDRESS]. Efficacy
The Full Analysis Set (FAS) will include all participants who (1) are randomized into the study 
and (2) have received at least 1 dose of study drug. Participants will be grouped according to the 
treatment to which they were randomized.
The Full Analysis Positive Set (FAPS) includes all participants who are (1) randomized into the 
study, (2) have received at least 1 dose of study drug, and (3) are SARS-CoV-2 positive at 
baseline as confirmed by [CONTACT_2237]. Participants will be grouped according to the 
treatment to which they were randomized. 
[IP_ADDRESS]. Safety
The primary analysis set for safety analyses is defined as the Safety Analysis Set, which will 
include all participants who (1) are randomized into the study and (2) have received at least 
1 dose of study drug. Participants will be grouped according to the treatment they received.
All data collected during treatment plus 30 days will be included in the safety summaries.
[IP_ADDRESS]. Virology
The Virology Analysis Set will include all participants who (1) are randomized into the study, 
(2) have received at least 1 dose of study treatment, and (3) have a baseline SARS-CoV-2 viral 
GS-5245 
Protoco l GS-US-611 -654 9 
[COMPANY_009] Sciences , Inc. Final 
Amendment4 
load greater than or equal to the lower limit of quantifi catio n (LLOQ ). Parti cipants will be 
grouped according to the ti·eatment they received. 
[IP_ADDRESS]. Phaima cokinetics 
The PK Analysis Set will include all rand omize d paiiicipants who received at least [ADDRESS_529455] 1 nonmissing PK concentration datum repo1ied by [CONTACT_419824]1y 
for each respective analyte . -
[IP_ADDRESS]. Biomai·kers 
The Biomai·ker Analysis Set will includ e all randomized paiiicipan ts who received at least [ADDRESS_529456] a sample collected for biomarker evaluation. 
8.3.2. Data Handling Conventions 
Natural logai·ithm ti·ansfo1 mati on for PK pai·ameters will be app lied for PK analysis. 
For summai y statistics, PK concenti·ation values below the limit of quantit ation will be ti·eated as 
zero at predose and one-half of the LLOQ for postdose time points. 
Laborato1y data that are continuous in nature but are less than the LLOQ or above the upper limit 
of quan titation , will be imputed to the value of the lower or upper limit plus or minu s 
1 significant digit, respectively ( eg, if the result of a continu ous laborato1y test is < 20, a value of 
19 will be assigned). 
Missing data can have an impact upon the inte1pretation of the study data. In general, values for 
missing data will not be impu ted. However , a missing preti·eatment laborato1y result would be 
ti·eated as nonnal (ie, no toxicity grade) for the laborato1y abno1mality summa1 y . 
All available data for paiiicipants that do not complete the study will be includ ed in data listings. 
8.4. Demographic and Baseline Characteristics Analysis 
Demographic and baseline measurem ents will be Sllllllnai-i zed using standai· d descriptive 
methods. 
Demographic Sllilllllai · ies will include sex, race/ethnicity, randomization s ti·atifica tion group, and 
age. For catego rical demograp hic and baseline chai·acteristics , a Cochran- Mante l-Haenszel test 
CONFIDENTIAL Page [ADDRESS_529457] will be used to compare treatment groups.
8.5. Efficacy Analysis
8.5.1. Primary Efficacy Analysis
The time to COVID-19 symptom alleviation is defined as follows: 
•For participants with symptom alleviation by [CONTACT_2006] 29 (event), time to COVID-[ADDRESS_529458] dose date plus 1.
•For participants who complete Day 29 of the study or discontinue from the study before 
Day 29 without symptom alleviation (censored), the time will be calculated as the last date 
on which the symptom alleviation is assessed by [CONTACT_2006] [ADDRESS_529459].
Handling of intercurrent events is defined in Section 8.5.3.
The median time to symptom alleviation and its 95% CI will be estimated by [CONTACT_419802]-Meier method. A stratified log-rank test with stratification factor included will 
be used to compare the treatment difference in time to COVID-[ADDRESS_529460] ratio 
(HR) and its 2-sided 95% CI. Stratification factor will be included as a covariate in the Cox 
proportional hazards model. 
The FAPS will be used for the primary efficacy endpoint analysis. The primary analysis for the 
primary efficacy endpoint will be repeated using the FAS.
Sensitivity analysis associated with the primary endpoint may be performed:
•A sensitivity analysis using a competing risk analysis approach will be provided, with 
intercurrent events (death or COVID-19–related hospi[INVESTIGATOR_059]) as the competing risk. 
•Missing symptom alleviation status will be imputed using multiple imputation assuming 
missing at random.
•Depending on the percentage of participants with other concomitant respi[INVESTIGATOR_419783](s) at baseline, a sensitivity analysis may be conducted using the respi[INVESTIGATOR_419784] (yes/no) at baseline as an additional stratification factor in the stratified 
log-rank test and as an additional covariate in the Cox proportional hazards model.
GS-5245
Protocol GS-US-611-6549 Final
[COMPANY_009] Sciences, Inc. Amendment 4
CONFIDENTIAL Page 67 12 December [ZIP_CODE].5.2. Secondary Efficacy Analyses
[IP_ADDRESS]. Key Secondary Efficacy Endpoints
Four alpha-controlled secondary efficacy endpoints are considered as the key secondary 
endpoints and will be tested in the following sequential order using a gatekeepi[INVESTIGATOR_120229]: 
•Time to COVID-19 symptom resolution by [CONTACT_2006] 29.
•Proportion of participants with moderate relapse of COVID-19 symptoms by [CONTACT_2006] 29.
•The proportion of participants with COVID-19–related MAVs or all-cause death by [CONTACT_2006] 29.
•Proportion of participants with COVID-19–related hospi[INVESTIGATOR_419766]-cause death by 
[CONTACT_2006] 29.
The time to COVID-19 symptom resolution will be analyzed in a similar manner to the primary 
endpoint using the FAPS.
Proportion of participants with moderate relapse of COVID-19 symptoms will be estimated with 
95% CIs including participants in the FAPS who have achieved short symptom recovery. 
The proportion of participants with MAVs or all-cause death by [CONTACT_2006] [ADDRESS_529461]. Similar analysis methods will be used for the proportion of participants with 
COVID-19–related hospi[INVESTIGATOR_419766]-cause death by [CONTACT_2006] 29.
Handling of intercurrent events for key secondary efficacy endpoints is defined in Section 8.5.3. 
8.5.3. Intercurrent Events
Handling of intercurrent events for the primary endpoint and secondary efficacy endpoints 
relevant to symptom duration and main clinical outcome measures (eg, hospi[INVESTIGATOR_059]/death) are 
shown in Table 11.
GS-5245
Protocol GS-US-611-6549 Final
[COMPANY_009] Sciences, Inc. Amendment 4
CONFIDENTIAL Page 68 12 December 2023Table 11. Handling of Intercurrent Events
Endpoint Intercurrent event Strategy Description
Hospi[INVESTIGATOR_419785]-19 or all-cause deathComposite 
policyHospi[INVESTIGATOR_419786]-19 or all-cause death means 
never achieve symptom 
alleviation/resolution (censored at 
Day 28)
Discontinue randomized 
treatment prior to symptom 
alleviation/resolution (due to 
AE, lack of efficacy, 
investigator's discretion, 
noncompliance with study drug, 
protocol violation, participant 
decision, lost to follow-up)Treatment 
policyIgnore the occurrence of intercurrent 
events (use observed outcome)Time to COVID-19 
symptom alleviation by 
[CONTACT_2006] 29
Time to COVID-19 
symptom resolution by 
[CONTACT_2006] 29
Use of rescue medicationComposite 
policyUse of rescue medication means 
never achieve symptom 
alleviation/resolution (censor at Day 
28)
Hospi[INVESTIGATOR_419785]-19 or all-cause death 
after short symptom recoveryComposite 
policyHospi[INVESTIGATOR_419786]-19 or all-cause death means 
moderate relapse/relapse
Discontinue randomized 
treatment after short symptom 
recovery (due to AE, lack of 
efficacy, investigator's 
discretion, noncompliance with 
study drug, protocol violation, 
participant decision, lost to 
follow-up)Treatment 
policyIgnore the occurrence of intercurrent 
events (use observed outcome)Proportion of 
participants with 
moderate relapse of 
COVID-19 symptoms 
by [CONTACT_2006] 29
Proportion of 
participants with 
relapse of COVID-19 
symptoms by [CONTACT_2006] 29
Use of rescue medication after 
short symptom recoveryComposite 
policyUse of rescue medication means 
moderate relapse/relapse
Discontinue randomized 
treatment prior to endpoint (due 
to AE, lack of efficacy, 
investigator's discretion, 
noncompliance with study drug, 
protocol violation, participant 
decision, lost to follow-up)Treatment 
policyIgnore the occurrence of intercurrent 
events (use observed outcome)Proportion of 
COVID-19–related 
hospi[INVESTIGATOR_419787]-cause death by 
[CONTACT_2006] 29
Proportion of 
participants with 
COVID-19-related 
MAVs or all-cause 
death by [CONTACT_2006] 29Use of rescue medicationTreatment 
policyIgnore the occurrence of intercurrent 
events (use observed outcome)
AE = adverse event; COVID-19 = coronavirus disease [ADDRESS_529462] dose of study drug will be summarized by [CONTACT_1570] (according to 
the study drug received). Data for the pretreatment period and after the date of last dose of study 
drug plus 30 days will be included in data listings.
8.6.1. Extent of Exposure
A participant’s extent of exposure to study drug data will be generated from the study drug 
administration data. Exposure data will be summarized by [CONTACT_1570]. 
8.6.2. Adverse Events
Clinical and laboratory AEs will be coded using the current version of the MedDRA. System 
organ class, high-level group term, high-level term, preferred term, and lower-level term will be 
attached to the clinical database.
Events will be summarized on the basis of the date of onset for the event. A treatment-emergent 
AE will be defined as any AE that begins on or after the date of first dose of study drug up to the 
date of last dose of study drug plus 30 days.
Summaries (number and percentage of participants) of treatment-emergent AEs (by [CONTACT_53428]) will be provided by [CONTACT_1570].
8.6.3. Laboratory Evaluations
Selected laboratory test data (using conventional units) will be summarized using only observed 
data. Data and change from baseline at all scheduled time points will be summarized.
Graded laboratory abnormalities will be defined using the grading scheme in DAIDS Table for 
Grading the Severity of Adult and Pediatric Adverse Events, Version 2.1 (corrected, July 2017). 
The DAIDS scale is available at:
https://rsc.niaid.nih.gov/sites/default/files/daidsgradingcorrectedv21.pdf
Incidence of treatment-emergent laboratory abnormalities, defined as values that increase at least 
[ADDRESS_529463] 
dose of study drug will be summarized by [CONTACT_1570]. If baseline data are missing, then any 
graded abnormality (ie, at least a Grade 1) will be considered treatment emergent. 
Laboratory abnormalities that occur before the first dose of study drug or after the participant has 
been discontinued from treatment for at least 30 days will be included in a data listing.
GS-5245
Protocol GS-US-611-6549 Final
[COMPANY_009] Sciences, Inc. Amendment 4
CONFIDENTIAL Page 70 12 December [ZIP_CODE].7. Adjustments for Multiplicity
The overall 2-sided type I error rate of 0.05 for the primary efficacy endpoint and key 
α-controlled secondary endpoints will be controlled using the Lan-DeMets approach with 
O’Brien-Fleming type spending function accompanying a gatekeepi[INVESTIGATOR_419788] (ie, the 
primary efficacy endpoint will be tested first and the key α-controlled secondary endpoints will 
be tested in a sequential manner only if the primary efficacy endpoint is met). 
An example O’Brien-Fleming stoppi[INVESTIGATOR_419789] 50% of planned participants reaching 
Day 29 or prematurely discontinuing from the study is: reject the null hypothesis with 1-sided 
P value ≤ 0.[ADDRESS_529464] the alternative hypothesis with 1-sided P value > 0.3495. The actual 
stoppi[INVESTIGATOR_419790]. If the efficacy 
stoppi[INVESTIGATOR_393023], the primary endpoint will not be tested 
again at the primary analysis.
8.8. Pharmacokinetic Analysis 
Plasma concentrations and PK parameters AUC tau, Ctau, and C max (and others, as available) for 
GS-441524 (metabolite of GS-5245) will be listed and summarized using descriptive statistics by 
[CONTACT_3148]. Exposure-response analysis for safety and/or efficacy may be conducted, if needed 
and sufficient data are available. 
8.9. Sample Size
A total sample size of approximately 1900 participants (assuming 90% are CoV-2 positive at 
baseline as confirmed by [CONTACT_2237]) provides approximately 87% power to detect a 
median difference of [ADDRESS_529465] (Version 6.5, module for 
log-rank test given accrual duration and study duration and 1 interim analysis using the 
Lan-DeMets approach with O’Brien-Fleming type spending function).
8.10. Data Monitoring Committee 
A multidisciplinary DMC consisting of non-[COMPANY_009] personnel will review the progress of the 
study, perform interim reviews of safety data, and provide recommendation to [COMPANY_009] whether 
the nature, frequency, and severity of AEs associated with study treatment warrant the early 
termination of the study in the best interests of the participant, whether the study should continue 
as planned, or whether the study should continue with modifications. The DMC may also 
provide recommendations as needed regarding study design.
While the DMC will be asked to advise [COMPANY_009] regarding future conduct of the study, including 
possible early study termination, [COMPANY_009] retains final decision-making authority on all aspects of 
GS-5245
Protocol GS-US-611-6549 Final
[COMPANY_009] Sciences, Inc. Amendment 4
CONFIDENTIAL Page 71 12 December 2023the study. If the DMC recommends stoppi[INVESTIGATOR_419791], a [COMPANY_009] Oversight 
Committee will be unblinded to review the DMC recommendation.
•The first DMC meeting will be based on data collected after the first [ADDRESS_529466] 
reached Day 29 or prematurely discontinued from the study, and will include safety data.
•Enrollment of adolescent participants (aged ≥ 12 to < 18 years), at US sites only, may 
commence after conclusion of the first DMC meeting.
The second DMC meeting will occur when approximately 50% of planned participants complete 
the Day 29 assessment, or prematurely discontinue from the study. The DMC meeting will 
include review of safety and formal evaluation of futility and efficacy. 
The significance level for futility and efficacy will be determined using the O’Brien-Fleming 
approach at the interim analysis and the final analysis. The overall significance level is set at 
5% (2 sided). 
GS-5245
Protocol GS-US-611-6549 Final
[COMPANY_009] Sciences, Inc. Amendment 4
CONFIDENTIAL Page 72 12 December [ZIP_CODE]. RESPONSIBILITIES
9.1. Investigator Responsibilities
9.1.1. Good Clinical Practice
The investigator will ensure that this study is conducted in accordance with ICH E6(R2) 
addendum to its guideline for GCP and applicable laws and regulations.
9.1.2. Financial Disclosure
The investigator and subinvestigators will provide prompt and accurate documentation of their 
financial interest or arrangements with [COMPANY_009] or proprietary interests in the study drug. This 
documentation must be provided before the investigator’s (and any subinvestigator’s) 
participation in the study. The investigator and subinvestigator agree to notify [COMPANY_009] of any 
change in reportable interests during the study and for [ADDRESS_529467]/Independent Ethics Committee Review and 
Approval
The investigator (or [COMPANY_009] as appropriate according to local regulations) will submit this 
protocol, ICF, and any accompanying material to be provided to the participant (such as 
advertisements, participant information sheets, or descriptions of the study used to obtain 
informed consent) to an IRB/IEC. The investigator will not begin any study participant activities 
until approval from the IRB/IEC has been documented and provided as a letter to the 
investigator.
Before implementation, the investigator will submit to and receive documented approval from 
the IRB/IEC for any modifications made to the protocol or any accompanying material to be 
provided to the participant after initial IRB/IEC approval, with the exception of those necessary 
to reduce immediate risk to study participants.
9.1.4. Informed Consent
The investigator is responsible for obtaining written informed consent from each individual 
participating in this study after adequate explanation of the aims, methods, objectives, and 
potential hazards of the study before undertaking any study-related procedures. The investigator 
must use the most current IRB/IEC-approved ICF for documenting written informed consent. 
Each ICF will be appropriately signed and dated by [CONTACT_98901]’s legally 
authorized representative, the person conducting the consent discussion, and an impartial witness 
(if required by [CONTACT_1744]/IEC or local requirements). 
GS-[ADDRESS_529468] ensure that participants’ anonymity will be strictly maintained and that 
their identities are protected from unauthorized parties. Only an identification code and any other 
unique identifier(s) as allowed by [CONTACT_1769] (such as year of birth) will be recorded on any form 
or biological sample submitted to [COMPANY_009], IRB/IEC, or the laboratory. Laboratory specimens 
must be labeled in such a way as to protect participant identity while allowing the results to be 
recorded to the proper participant. Refer to specific laboratory instructions or in accordance with 
local regulations. Note: The investigator must keep a screening log with details for all 
participants screened and enrolled in the study, in accordance with the site procedures and 
regulations. Participant data will be processed in accordance with all applicable regulations. 
The investigator agrees that all information received from [COMPANY_009], including but not limited to the 
IB, this protocol, eCRFs, study drug information, and any other study information, remains the 
sole and exclusive property of [COMPANY_009] during the conduct of the study and thereafter. This 
information is not to be disclosed to any third party (except employees or agents directly 
involved in the conduct of the study or as required by [CONTACT_2371]) without prior written consent from 
[COMPANY_009]. The investigator further agrees to take all reasonable precautions to prevent the 
disclosure by [CONTACT_210185].
9.1.6. Study Files and Retention of Records
The investigator must maintain adequate and accurate records to enable the conduct of the study 
to be fully documented and the study data to be subsequently verified. These documents should 
be classified into at least the following 2 categories: (1) investigator’s study file and 
(2) participant clinical source documents.
The investigator’s study file will contain the protocol/amendments, eCRFs, IRB/IEC, and 
governmental approval with correspondence, the ICF(s), drug records, staff curriculum vitae and 
authorization forms, and other appropriate documents and correspondence.
The required source data should include sequential notes containing at least the following 
information for each participant:
•Participant identification
GS-5245
Protocol GS-US-611-6549 Final
[COMPANY_009] Sciences, Inc. Amendment 4
CONFIDENTIAL Page 74 12 December 2023•Documentation that participant meets eligibility criteria (ie, medical history, physical 
examination, and confirmation of diagnosis [to support inclusion and exclusion criteria])
•Documentation of the reason(s) a consented participant is not enrolled
•Participation in study (including study number)
•Study discussed and date of informed consent
•Dates of all visits
•Documentation that protocol-specific procedures were performed
•Results of efficacy parameters, as required by [CONTACT_760]
•Start and end date (including dose regimen) of study drug, including dates of dispensing and 
return
•Record of all AEs and other safety parameters (start and end date; causality and severity) and 
documentation that adequate medical care has been provided for any AE
•Concomitant medication (start and end date; dose if relevant; dose changes)
•Date of study completion and reason for early discontinuation, if it occurs
All clinical study documents must be retained by [CONTACT_114824] [ADDRESS_529469] approval of a marketing application in an ICH 
region (ie, the US, the EU, or Japan) and until there are no pending or planned marketing 
applications in an ICH region; or, if no application is filed or if the application is not approved 
for such indication, for [ADDRESS_529470] from the site.
GS-5245
Protocol GS-US-611-6549 Final
[COMPANY_009] Sciences, Inc. Amendment 4
CONFIDENTIAL Page 75 12 December [ZIP_CODE].1.7. Electronic Case Report Forms
An eCRF casebook will be completed by [CONTACT_419825] (EDC) system unless otherwise 
directed. The eCRF casebook will only capture the data required per the protocol schedule of 
events and procedures, unless collected by a non-EDC vendor system (eg, central laboratory). 
The Inclusion/Exclusion Criteria and Enrollment eCRFs should be completed only after all data 
related to eligibility are available. Data entry should be performed in accordance with the eCRF 
Completion Guidelines provided by [CONTACT_10866]. Subsequent to data entry, a study monitor may 
perform source data verification. System-generated or manual queries will be issued in the EDC 
system as data discrepancies are identified by [CONTACT_419826], correctness, and consistency. The site investigator, 
site coordinator, or other designee is responsible for responding to the queries in a timely 
manner, within the system, either by [CONTACT_204983], 
and providing the reason for the update (eg, data entry error). Original entries as well as any 
changes to data fields will be stored in the audit trail of the system. Regular oversight by [CONTACT_28824] [INVESTIGATOR_419792]. At a minimum, before any 
interim, final, or other time points (as instructed by [CONTACT_10866]), the investigator will apply his/her 
electronic signature [CONTACT_419829]. At the conclusion of the study, [COMPANY_009] will 
provide the site investigator with a read-only archive copy of the data entered. This archive must 
be stored in accordance with the records retention requirements outlined in Section 9.1.6.
9.1.8. Investigator Inspections
The investigator will make available all source documents and other records for this study to 
[COMPANY_009]’s appointed study monitors, to IRB/IEC, or to regulatory authority or health authority 
inspectors.
9.1.9. Protocol Compliance
The investigator is responsible for ensuring the study is conducted in accordance with the 
procedures and evaluations described in this protocol.
9.2. Sponsor Responsibilities
9.2.1. Protocol Modifications
Protocol modifications, except those intended to reduce immediate risk to study participants, 
may be made only by [CONTACT_10866]. The investigator must submit all protocol modifications to the 
IRB/IEC in accordance with local requirements and receive documented IRB/IEC approval 
before modifications can be implemented.
GS-5245
Protocol GS-US-611-6549 Final
[COMPANY_009] Sciences, Inc. Amendment 4
CONFIDENTIAL Page 76 12 December [ZIP_CODE].2.2. Study Reports and Publications
A clinical study report (CSR) will be prepared and provided to the regulatory agency(ies) when 
applicable and in accordance with local regulatory requirements. [COMPANY_009] will ensure that the 
report meets the standards set out in the ICH Guideline for Structure and Content of Clinical 
Study Reports (E3). Note that an abbreviated report may be prepared in certain cases. For studies 
with sites in countries following the EU Regulation No. 536/2014, a CSR will be submitted 
within 1 year (6 months for pediatric studies, in accordance with Regulation [EC] 
No. 1901/2006) after the global end of study (as defined in Section 3.4.2). 
Investigators in this study may communicate, orally present, or publish study data in scientific 
journals or other scholarly media in accordance with the [COMPANY_009] clinical trial agreement.
9.3. Joint Investigator/Sponsor Responsibilities
9.3.1. Payment Reporting
Investigators and their study personnel may be asked to provide services performed under this 
protocol (eg, attendance at investigator meetings). If required under the applicable statutory and 
regulatory requirements, [COMPANY_009] will capture and disclose to federal and state agencies any 
expenses paid or reimbursed for such services, including any clinical study payments, meal 
and/or travel expenses or reimbursements, consulting fees, and any other transfer of value.
9.3.2. Access to Information for Monitoring
In accordance with regulations and guidelines, the study monitor must have direct access to the 
investigator’s source documentation and any participant records in order to verify the adherence 
to the protocol and the accuracy of the data recorded in the eCRF. The study monitor is 
responsible for routine review of the eCRF form at regular intervals throughout the study to 
verify adherence to the protocol and the completeness, consistency, and accuracy of the data 
being entered on them. The investigator agrees to cooperate with the study monitor to ensure that 
any problems detected through any type of monitoring (central, off-site, or on-site monitoring) 
are resolved.
9.3.3. Access to Information for Auditing or Inspections
Representatives of regulatory authorities or [COMPANY_009] may conduct inspections or audits of the 
clinical study. If the investigator is notified of an inspection by a regulatory authority, the 
investigator agrees to notify the [COMPANY_009] study monitor immediately. The investigator agrees to 
provide to representatives of a regulatory agency or [COMPANY_009] access to records, facilities, and 
personnel for the effective conduct of any inspection or audit.
GS-5245
Protocol GS-US-611-6549 Final
[COMPANY_009] Sciences, Inc. Amendment 4
CONFIDENTIAL Page 77 12 December [ZIP_CODE].3.4. Study Discontinuation
[COMPANY_009] reserves the right to terminate the study at any time, and the investigator has the right to 
terminate the study at his or her site. Should this be necessary, both parties will arrange 
discontinuation procedures and notify the participants, appropriate regulatory authority(ies), and 
IRB/IEC. In terminating the study, [COMPANY_009] and the investigator will ensure that adequate 
consideration is given to the protection of the participants’ interests.
GS-5245
Protocol GS-US-611-6549 Final
[COMPANY_009] Sciences, Inc. Amendment 4
CONFIDENTIAL Page 78 12 December 202310. REFERENCES
Azzolini E, Levi R, Sarti R, Pozzi C, Mollura M, Mantovani A, et al. Association Between 
BNT162b2 Vaccination and Long COVID After Infections Not Requiring 
Hospi[INVESTIGATOR_419793]. JAMA 2022;328 (7):676-8.
Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 
1976;16:31-41.
Cox RM, Wolf JD, Lieber CM, Sourimant J, Lin MJ, Babusis D, et al. Oral prodrug of 
remdesivir parent GS-[ADDRESS_529471] SARS-CoV-2 in ferrets. 
Nature communications 2021;12 (1):6415.
HealthMeasures, National Institutes of Health (NIH). Intro to PROMIS®. Available at: 
https://www.healthmeasures.net/explore-measurement-systems/promis/intro-to-
promis. Accessed: [ADDRESS_529472] Updated: [ADDRESS_529473]. 2022:
Jayk Bernal A, Gomes da Silva MM, Musungaie DB, Kovalchuk E, Gonzalez A, Delos Reyes V, 
et al. Molnupi[INVESTIGATOR_419794]-19 in Nonhospi[INVESTIGATOR_34297]. N 
Engl J Med 2022;386 (6):509-20.
Mackman RL, Hui HC, Perron M, Murakami E, Palmiotti C, Lee G, et al. Prodrugs of a 1'-CN-4-
Aza-7,9-dideazaadenosine C-Nucleoside Leading to the Discovery of Remdesivir 
(GS-5734) as a Potent Inhibitor of Respi[INVESTIGATOR_419795]. J Med Chem 2021;64 (8):5001-17.
Pi[INVESTIGATOR_7929] J, Babusis D, Vermillion MS, Subramanian R, Barrett K, Lye D, et al. Intravenous delivery 
of GS-441524 is efficacious in the African green monkey model of SARS-CoV-2 
infection. Antiviral Res 2022;203:105329.
Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and 
activity impairment instrument. Pharmacoeconomics 1993;4 (5):353-65.
Romano C, Fehnel S, Stoddard J, Sadoff J, Lewis S, McNulty P, et al. Development of a novel 
patient-reported outcome measure to assess signs and symptoms of COVID-19. J 
Patient Rep Outcomes 2022;6 (1):85.
U. S. Department of Health & Human Services (DHHS), Food and Drug Administration (FDA), 
Center for Drug Evaluation amd Research (CDER), Center for Biologic 
Evaluation and Research (CBER). Assessing COVID-19-Related Symptoms in 
Outpatient Adult and Adolescent Subjects in Clinical Trials of Drugs and 
Biological Products for COVID-19 Prevention or Treatment Guidance for 
Industry. September, 2020.
GS-5245
Protocol GS-US-611-6549 Final
[COMPANY_009] Sciences, Inc. Amendment 4
CONFIDENTIAL Page 79 12 December 2023VEKLURY, [COMPANY_009] Sciences Inc. VEKLURY® (remdesivir) for injection, for intravenous use. 
VEKLURY® (remdesivir) injection, for intravenous use. U.S. Prescribing 
Information. Foster City, CA. Revised: June. 2022a:
Veklury, [COMPANY_009] Sciences Ireland UC. Veklury [ADDRESS_529474] Characteristics. County Cork, Ireland. Revised 
April. 2022b:
GS-[ADDRESS_529475]
FOSTER CITY, CA [ZIP_CODE]
STUDY ACKNOWLEDGMENT
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and 
Safety of GS-5245 for the Treatment of COVID-19 in Nonhospi[INVESTIGATOR_419796]-US-611-6549, Amendment 4 Protocol, 12 December 2023
This protocol has been approved by [CONTACT_10869], Inc. The following signature [CONTACT_10883].
[See appended electronic signature]
Sr Assoc Clinical Development 
DirectorSignature
[See appended electronic signature]
Date
INVESTIGATOR STATEMENT
I have read the protocol, including all appendices, and I agree that it contains all necessary 
details for me and my staff to conduct this study as described. I will conduct this study as 
outlined herein and will make a reasonable effort to complete the study within the time 
designated.
I will provide all study personnel under my supervision copi[INVESTIGATOR_10805], Inc. I will discuss this material with them to ensure 
that they are fully informed about the drugs and the study.
Principal Investigator [CONTACT_5627] (Printed) Signature
[CONTACT_419830]-[ADDRESS_529476] 
1 Country 
Following EU 
Regulation 
No. 536/2014Authorized 
in at Least 1 
ICH CountryAuthorized by 
[CONTACT_419827]-5245 Study drug No No No
EU = European Union; ICH = International Council for Harmonisation (of Technical Requirements for Pharmaceuticals for 
Human Use) 
GS-[ADDRESS_529477] been identified for this study. 
These risks can be summarized as follows:
1) Study drug supplies to participants and sites:
a) Participants may be unable to return to the site for a number of visits to get the study 
drug, or the site may be unable to accept any participant visits. Without study drugs, the 
participant would not be able to continue receiving the study drug as planned per 
protocol.
Mitigation plan: Study drug supplies may be provided to the participant from the site 
without a clinic visit, once it is confirmed that the participant may safely continue on 
study drug as determined by [CONTACT_458]. A remote study visit, via phone or 
video conferencing, must be performed before remote study drug resupply. At the earliest 
opportunity, the site will schedule in-person participant visits and return to the protocol’s 
regular schedule of assessments. A qualified courier may be utilized to ship the study 
drug from sites to study participants if permitted by [CONTACT_210190]/institutional review board/regulatory authority as applicable and with 
sponsor's approval.
b) Shipments of study drug could be delayed because of transportation issues. Without study 
drug, the participant would not be able to continue receiving the study drug as planned 
per protocol.
Mitigation plan: The site’s study drug inventory should be closely monitored. Site staff 
should notify [COMPANY_009] or delegate if they foresee shortage in study drug inventory or if 
there is any interruption in local shippi[INVESTIGATOR_54609]. [COMPANY_009] will continue to monitor 
inventory at the study drug depot and investigational sites. Manual shipments will be 
triggered as necessary.
2) Participant safety monitoring and follow-up:
a) Participants may be unable or unwilling to come to the investigational site for their 
scheduled study visits as required per protocol.
Mitigation plan: For participants who may be unable or unwilling to visit the 
investigational site for their scheduled study visits as required per protocol, the principal 
investigator [INVESTIGATOR_419797] a remote study visit, via phone or video 
conferencing, to assess the participant within the target visit window date whenever 
possible. During the remote study visit, the following information at minimum will be 
reviewed: 
GS-5245
Protocol GS-US-611-6549 Final
[COMPANY_009] Sciences, Inc. Amendment 4
CONFIDENTIAL Page 84 12 December 2023i) Confirm if participant has experienced any AEs/SAEs/special situations (including 
pregnancy) and follow up on any unresolved AEs/SAEs.
ii) Review the current list of concomitant medications and document any new 
concomitant medications.
iii) If applicable, confirm electronic diary questionnaires and patient-reported outcomes 
have been completed and transmitted.
iv) If applicable, confirm the participant’s study drug supply is sufficient to last until the 
next planned visit date. If study drug resupply is needed, it will be provided as 
described above in (1).
v) If applicable, remind the participant to maintain current dosing and to keep all 
dispensed study drug kits for return at the next on-site visit.
b) Participants may be unable or unwilling to travel to the site for planned assessments (eg, 
safety blood draws); hence samples may not be sent for central laboratory analyses.
Mitigation plan: Local laboratories or other vendors may be utilized as appropriate to 
monitor participant safety until the participant can return to the site for their regular 
follow-up per protocol. Any changes in the party conducting laboratory assessments for 
the study because of the pandemic will be documented accordingly. Pregnancy testing 
may be performed using a home urine pregnancy test if local laboratory pregnancy 
testing is not feasible.
c) Participants may be unable or unwilling to attend the study visit to sign an updated 
informed consent form version.
Mitigation plan: The site staff will follow their approved consent process and remain in 
compliance with the local ethics committee/institutional review board and national laws 
and regulations. Remote consent will be allowed if has been approved by [CONTACT_210190]/institutional review board. The consent process will be documented and 
confirmed by [CONTACT_54674].
3) Protocol and monitoring compliance:
a) Protocol deviations may occur in case scheduled visits cannot be conducted as planned 
per protocol.
Mitigation plan: If it is not possible to complete a required procedure, an unscheduled 
visit should be conducted as soon as possible when conditions allow. The situation should 
be recorded and explained as a protocol deviation. Any missed participant visits or 
deviation to the protocol because of the pandemic must be reported in the eCRF and 
described in the clinical study report (CSR). Any remote study visits that are conducted 
in lieu of clinic visits because of the pandemic will be documented as a protocol 
deviation related to the pandemic.
GS-5245
Protocol GS-US-611-6549 Final
[COMPANY_009] Sciences, Inc. Amendment 4
CONFIDENTIAL Page 85 12 December 2023b) Study monitors may be unable to carry out source data review, source data verification, 
or study drug accountability or assess protocol and Good Clinical Practice compliance. 
This may lead to delays in source data verification, an increase in protocol deviations, or 
underreporting of AEs.
Mitigation plan: The study monitor is to remain in close communication with the site to 
ensure data entry and query resolution. Remote source data verification may be arranged 
if allowed by [CONTACT_54675]. The study monitor is to 
reference the Study Monitoring Plan for guidance on how to conduct an off-site 
monitoring visit. The study staff is to save and document all relevant communication in 
the study files. The status of sites that cannot accept monitoring visits and/or participants 
on site must be tracked centrally and updated on a regular basis.
4) Missing data and data integrity:
There may be an increased amount of missing data because of participants missing 
visits/assessments. This could have an impact on the analysis and the interpretation of 
clinical study data. 
Mitigation plan: Implications of a pandemic on methodological aspects for the study will be 
thoroughly assessed and documented, and relevant actions will be taken as appropriate 
(eg, modification of the statistical analysis plan) and in compliance with regulatory 
authorities’ guidance. Overall, the CSR will describe the impact of the pandemic on the 
interpretability of study data.
Risks will be assessed continuously, and temporary measures will be implemented to mitigate 
these risks as part of a mitigation plan, as described above. These measures will be 
communicated to the relevant stakeholders as appropriate and are intended to provide alternate 
methods that will ensure the evaluation and assessment of the safety of participants who are 
enrolled in this study. 
Since these potential risks are considered mitigated with the implementation of these measures, 
the expected benefit-risk assessment of GS-5245 in study participants remains unchanged. 
GS-5245
Protocol GS-US-611-6549 Final
[COMPANY_009] Sciences, Inc. Amendment 4
CONFIDENTIAL Page 86 12 December 202311.4. Pregnancy Precautions, Definition of Childbearing Potential, and 
Contraceptive Requirements
1) Definitions
a. Definition of Childbearing Potential
For the purposes of this study, a participant assigned female at birth is considered of childbearing 
potential following the initiation of puberty (Tanner stage 2, Tanner staging only required if the 
participant is believed to be prepubescent) until becoming postmenopausal, or unless the 
participant is permanently sterile or has medically documented ovarian failure. Permanent 
sterilization includes hysterectomy, bilateral oophorectomy, or bilateral salpi[INVESTIGATOR_90254] a 
participant assigned female at birth of any age.
Participants assigned female at birth are considered to be in a postmenopausal state when they 
are at least [ADDRESS_529478] 12 months also may be considered postmenopausal if their 
follicle-stimulating hormone level is in the postmenopausal range and they are not using 
hormonal contraception or hormonal replacement therapy.
b. Definition of Fertility in a Participant Assigned Male at Birth
For the purposes of this study, a participant assigned male at birth is considered fertile after the 
initiation of puberty unless the participant is permanently sterile by [CONTACT_419828].
2) Contraception Requirements for Participants Assigned Female at Birth and of 
Childbearing Potential
a. Study Drug Effects on Pregnancy and Hormonal Contraception
GS-[ADDRESS_529479] is noted in early pregnancy 
based on nonclinical data. An increased rate of adverse fetal effects, including postimplantation 
loss and fetal visceral malformations related to the development of the heart, blood vessels, and 
liver, were noted in rabbits administered GS-5245 250 mg/kg/day. Data from clinical 
pharmacokinetic interaction studies of GS-[ADDRESS_529480] version of the investigator’s 
brochure for additional information.
b. Contraception Requirements for Participants Assigned Female at Birth and of 
Childbearing Potential
The inclusion of participants assigned female at birth and of childbearing potential requires the 
use of highly effective contraceptive measures with a failure rate of less than 1% per year. They 
must have a negative pregnancy test at the screening visit before randomization. A pregnancy 
test will also be performed at Day [ADDRESS_529481] agree to 1 of the 
following contraceptive methods:
Complete abstinence from intercourse of reproductive potential. Abstinence is an acceptable 
method of contraception only when it is in line with the participant’s preferred and usual 
lifestyle. 
Or
Consistent and correct use of 1 of the following methods of birth control listed below: 
•Hormonal or nonhormonal intrauterine device (IUD) 
•Subdermal contraceptive implant
•Bilateral tubal occlusion (upon medical assessment of surgical success)
•Vasectomy in the partner assigned male at birth (upon medical assessment of surgical 
success)
Or 
Participants assigned female at birth and of childbearing potential who wish to use a hormonally 
based method must use it in conjunction with a barrier method, preferably a male condom. 
Hormonal methods are restricted to those associated with the inhibition of ovulation. Hormonally 
based contraceptives and barrier methods permitted for use in this protocol are as follows:
•Hormonal methods (each method must be used with a barrier method, preferably male 
condom)
Oral contraceptives (either combined or progesterone only)
Injectable progesterone
Transdermal contraceptive patch
Contraceptive vaginal ring
•Barrier methods (each method must be used with a hormonal method)
Male condom (with or without spermicide)
Female condom (with or without spermicide)
Diaphragm with spermicide
GS-5245
Protocol GS-US-611-6549 Final
[COMPANY_009] Sciences, Inc. Amendment 4
CONFIDENTIAL Page 88 12 December 2023Cervical cap with spermicide
Sponge with spermicide
Inclusion of methods of contraception in this list of permitted methods does not imply that the 
method is approved in any country or region. Methods should only be used if locally approved. 
Participants assigned female at birth and of childbearing potential must also refrain from egg 
donation and in vitro fertilization during treatment and until the end of contraception 
requirement.
The above requirements apply only as specified, and not to sexual encounters in which 
pregnancy is not a possible outcome. 
3) Contraception Requirements for Participants Assigned Male at Birth
It is theoretically possible that a relevant systemic concentration of study drug may be achieved 
in a partner assigned female at birth from exposure to the participant’s seminal fluid and pose a 
potential risk to an embryo/fetus. A participant assigned male at birth with a partner assigned 
female at birth and of childbearing potential must use highly effective contraceptive measures 
with a failure rate of less than 1% per year through at least [ADDRESS_529482] also refrain from sperm donation or cryopreservation of 
germ cells during treatment and until the end of contraception requirement.
The above requirements apply only as specified, and not to sexual encounters in which 
pregnancy is not a possible outcome. 
4) Unacceptable Birth Control Methods
Birth control methods that are unacceptable include periodic abstinence (eg, calendar, ovulation, 
symptothermal, postovulation methods), withdrawal (coitus interruptus), spermicides only, and 
lactational amenorrhea method. A female condom and a male condom should not be used 
together.
5) Procedures to Be Followed in the Event of Pregnancy
Participants assigned female at birth will be instructed to notify the investigator if they become 
pregnant or suspect they are pregnant at any time from start of the study to [ADDRESS_529483] also report the 
information to the investigator. Instructions for reporting pregnancy, partner pregnancy, and 
pregnancy outcome are outlined in Section [IP_ADDRESS]. 
GS-5245
Protocol GS-US-611-6549 Final
[COMPANY_009] Sciences, Inc. Amendment 4
CONFIDENTIAL Page 89 12 December 202311.5. Underlying Medical Conditions Associated With Higher Risk for Severe 
COVID-19
•Obesity (body mass index [BMI] ≥ 30 kg/m2 for those ≥ 18 years or > 95th percentile in those 
≥ 12 but < 18 years of age).
•Diabetes mellitus, type 1 and type 2.
•Heart failure, coronary artery disease, or cardiomyopathies.
•Chronic kidney disease, or undergoing dialysis.
•Chronic liver disease, limited to cirrhosis, nonalcoholic steatohepatitis (NASH), alcoholic 
liver disease, and autoimmune hepatitis.
•Chronic lung diseases limited to: 
Chronic obstructive pulmonary disease.
Interstitial lung disease.
Cystic fibrosis.
Pulmonary hypertension.
Bronchiectasis.
•Current pulmonary embolism.
•Moderate to severe asthma (or asthma of any severity participants ≥ 12 and < 18 years of 
age).
•Active pulmonary tuberculosis.
•Cerebrovascular disease.
•Down syndrome.
•Pregnancy.
•One or more of the following immunocompromising conditions or immunosuppressive 
treatments:
Receiving chemotherapy or other therapi[INVESTIGATOR_72911].
Hematologic malignancy (active or in remission).
GS-5245
Protocol GS-US-611-6549 Final
[COMPANY_009] Sciences, Inc. Amendment 4
CONFIDENTIAL Page 90 12 December 2023History of a hematopoietic stem cell or a solid organ transplant.
Human immunodeficiency virus infection: not on antiretroviral therapy or with cluster of 
differentiation 4+ cell count < 200 cells per cubic millimeter.
Primary immunodeficiencies.
Taking systemic immunosuppressive agents (eg, high-dose corticosteroids [ie, ≥ 20 mg of 
prednisone or equivalent per day when administered for 2 or more weeks], alkylating 
agents, antimetabolites, transplant-related immunosuppressive drugs, cancer 
chemotherapeutic agents classified as severely immunosuppressive, tumor necrosis factor 
(TNF) blockers, and other biologic agents that are immunosuppressive or 
immunomodulatory).
GS-[ADDRESS_529484] access and for generalizability of study resul ts, included adolescents 
(age :C::12 to< 18 years) in the US only at pa1ticipating sites. Enro lment may 
commence after the first DMC meeting . 
CONFIDENTIAL Page 92 Final 
Amendment4 
Protocol Section 
Sections 6.1.1, 6.3.8, 
and7.5.l 
Table 1, 
Sections [IP_ADDRESS], 4.2, 
4.3, 6.1, 6. 1.1, [IP_ADDRESS], 
and 8.10 
12 December 2023 
GS-5245
Protocol GS-US-611-6549 Final
[COMPANY_009] Sciences, Inc. Amendment 4
CONFIDENTIAL Page 93 12 December 202311.8. Amendment History
High-level summaries of the history of this study’s amendments are provided in tabular form in 
the subsections below (from most recent amendment to oldest), with changes listed in each table 
in order of importance. Minor changes such as the correction of typographic errors, grammar, or 
formatting are not detailed.
A separate tracked change (red-lined) document comparing protocol amendment 3 to this 
amendment will be made available upon the publication of this protocol.
11.8.1. Amendment 4 (12 December 2023)
Rationale for Key Changes Included in Amendment [ADDRESS_529485] the current clinical outcomes 
of COVID-19.Synopsis, Sections 
2, [IP_ADDRESS], and [IP_ADDRESS] 
The definition of the primary efficacy analysis set was clarified.Sections [IP_ADDRESS], 8.5.1, and 
[IP_ADDRESS]
The definition of the virology analysis set was clarified. Section [IP_ADDRESS]
The futility stoppi[INVESTIGATOR_419798].Synopsis, Sections 8.7 and 
8.9
Minor changes included to provide clarification. Throughout, as needed
11.8.2. Amendment 3 (21 March 2023)
Rationale for Key Changes Included in Amendment [ADDRESS_529486] of underlying medical conditions 
associated with higher risk for severe COVID-19 to align with current clinical 
practice and COVID-19 epi[INVESTIGATOR_419799]. Synopsis, Section 4.3, and 
Appendix 11.5
Provided clarification on pregnancy reporting period for both participant 
pregnancies and partner pregnancies to ensure alignment throughout the protocol.Section [IP_ADDRESS] and 
Appendix 11.[ADDRESS_529487] 
also been included. Sections [IP_ADDRESS].1.2, 
[IP_ADDRESS].2.2, and 5.[ADDRESS_529488] at screening is already being performed, and 
clarification of study drug bottle return on Day 10.Table 1
Addition of definitions for medically attended visits and COVID-19–related 
hospi[INVESTIGATOR_059].Section [IP_ADDRESS]
Prior and concomitant medications that are prohibited was expanded to include 
ensitrelvir.Section 5.4.[ADDRESS_529489] typographic errors. Throughout, as needed
GS-5245
Protocol GS-US-611-6549 Final
[COMPANY_009] Sciences, Inc. Amendment 4
CONFIDENTIAL Page 94 12 December 202311.8.3. Amendment 2 (20 January 2023)
Rationale for Key Changes Included in Amendment 2 Affected Sections
Patient-reported outcome (PRO) tools were updated to minimize participant 
noncompliance with data reporting and interference of missing data with endpoint 
interpretability, per Food and Drug Administration (FDA) advice. Procedures to 
minimize missing PRO data were added.Appendix 11.5 and 
Section [IP_ADDRESS].[ADDRESS_529490] of SARS-CoV-2 lineage on key 
endpoints, and sensitivity analysis using the respi[INVESTIGATOR_419800] 
(yes/no) at baseline was added for the primary efficacy analysis were added .Synopsis, Sections 2, 8.1.1, 
[IP_ADDRESS], 8.5.1, and 8.5.3
Inclusion criterion “5” was updated to indicate the severity of disease symptoms 
as per FDA guidance.
Additionally, exclusion criterion “12” was updated to exclude participants with 
prior or current elevated bilirubin level (≥ 2  ULN; ≥ 3  ULN for participants 
with Gilbert’s syndrome).Synopsis, Section 4.2
Data of Phase 1 drug-drug interaction (DDI) were added and the restrictions on 
coadministration of acid-reducing agents removed, and hormonal contraceptive 
measures amended, to reflect DDI study conclusions. Sections [IP_ADDRESS].2.2, and 
5.4.1, and Appendix 11.3
Clarification was added noting a [COMPANY_009] internal unblinded team will be involved 
in planned interim unblinding only upon DMC recommendation. Synopsis and Section 5.1.3
PK parameters were specified for the PK analysis of GS-441524 (metabolite of 
GS-5245).Synopsis, Sections 2 and 8.8
Clarification was added regarding the PK samples collections for the participants 
in the  Table 1 (footnote “p”) and 
Section [IP_ADDRESS]
Additional text was included regarding UV protection measure recommendation 
(pending phototoxicity evaluation of GS-5425).Section 5.3
Clarification regarding discontinuation of participants from the study drug in case 
of Grade 4 clinically significant laboratory abnormality or clinical event, and was 
similarly updated for Grade 3. Sections [IP_ADDRESS] and [IP_ADDRESS]
A clarification was added regarding the type of nasal swab samples to be collected 
per FDA feedback.Study schema, Table 1, 
Sections 6.3.4 and [IP_ADDRESS].[ADDRESS_529491] typographic errors. Throughout, as needed
CCI
CCI
GS-5245
Protocol GS-US-611-6549 Final
[COMPANY_009] Sciences, Inc. Amendment 4
CONFIDENTIAL Page 95 12 December 202311.8.4. Amendment 1 (05 December 2022)
Rationale for Key Changes Included in Amendment [ADDRESS_529492] Phase 3 
objectives.Synopsis, Tables 1 and 8, 
Sections 2, 6, and 8
Changes to the visit schedule to optimize characterization of viral kinetics and 
detection of any potential resistance-associated mutations.Table 1 and Section 6
Inclusion and exclusion criteria were revised to incorporate FDA feedback on the 
study population. Synopsis, Sections 4.2, 4.3, 
and Appendix 11.4
An optional observational long COVID-19 assessment using observational data 
(obtain, store, and use existing health records data to assess long COVID-19 
symptoms and conditions) to evaluate the potential effect of GS-5245 on the 
incidence and persistence of long COVD-19 sequelae is only applicable to 
participants in the Unites States (US) at participating sites.Sections 6.1.1, 6.3.8, and 
7.5.[ADDRESS_529493] access and for generalizability of study results, included 
adolescents (age ≥ 12 to < 18 years) in the US only at participating sites. 
Enrolment may commence after the first DMC meeting.Table 1, Sections [IP_ADDRESS], 
4.2, 4.3, 6.1, 6.1.1, [IP_ADDRESS], 
and 8.[ADDRESS_529494] typographic errors. Throughout, as needed
CCI-
protocol GS-US-611-6549 amd-4
ELECTRONIC SIGNATURES
Signed by [CONTACT_4232]
(dd-MMM-
yyyy hh:mm:ss)
Clinical Development
eSigned13-Dec-2023
00:17:30
[COMPANY_003]